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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a five-year survival
rate of 8%. Oncogenic KRAS mutation is found in greater than 95% of PDAC cases, but
additional mutations or injury are required for disease initiation and progression.
Chromatin remodeling protein ATRX has been previously implicated in DNA repair,
replication and maintaining genomic stability. I hypothesized that loss of ATRX could
increase the susceptibility of pancreatic tissue to pancreatic injury or KRAS-mediated
damage. In this study, combination of inducible ATRX loss in adult mice with recurrent
pancreatic injury or oncogenic KRAS activation resulted in increased pancreatic damage,
including fibrosis, inflammation and acinar-to-ductal metaplasia. Interestingly, this effect
was gender-specific, causing pancreatic damage exclusively in female mice with ATRX
loss/KRAS activation. This study defines a novel role for ATRX within the exocrine
pancreas, and provides insight into the epigenetic factors that can influence susceptibility
to pancreatic disease.

Keywords
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Chapter 1

1

Introduction

The pancreas is an organ of endodermal origin, which develops from the embryonic
foregut (Jørgensen et al., 2007). The pancreas is divided into two functional
compartments; the endocrine portion and the exocrine portion. The endocrine portion
comprises approximately 1-2% of total pancreatic mass, acts to regulate glucose
homeostasis and consists of cell clusters called islets of Langerhans (Murtaugh and
Melton et al., 2003). There are five types of endocrine cells present with pancreatic islets
- b-cells, a-cells, d cells, PP cell and e cells, which produce the hormones insulin,
glucagon, somatostatin, pancreatic polypeptide and ghrelin respectively (Murtaugh and
Melton, 2003; Gittes, 2009).

The exocrine portion of the pancreas, comprising the other 98-99% of total pancreatic
mass, is responsible for the production and secretion of digestive enzymes to aid in the
digestion and absorption of food (Shih et al., 2013). Cell types within the exocrine
pancreas include pancreatic acinar cells, stellate cells, centroacinar cells and ductal cells
(Cleveland et al., 2012). The functional unit of the exocrine pancreas are the pancreatic
acinar cells, which are grouped into acini and have well-established basal-luminal
polarity (Shih et al., 2013; Figure 1.1). Centroacinar cells are located in the transitional
region between acinar cells and the ductal epithelium, which forms increasingly larger
ductal structures before joining with the common bile duct (Cleveland et al., 2012).
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Acinar cells produce and store zymogen granules containing inactive digestive enzymes.
Following food ingestion, acinar cells are stimulated by cholecystokinin to exocytose
their zymogen granules into adjacent pancreatic ducts. These granules move through the
pancreatic ductal system and eventually drain into the duodenum of the small intestine to
become active and assist in digestion (Shih et al., 2013). This thesis will focus on factors
within the pancreatic acinar cell that increase susceptibility to diseases of the exocrine
pancreas, including pancreatitis and pancreatic ductal adenocarcinoma (PDAC).
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Acinar cell

Centroacinar cell

Duct cell
Acinus

Zymogen granules
Pancreatic stellate cell

Figure 1.1. Schematic of major cell types within the exocrine pancreas. Acinar cells
are organized into acini, surrounding a central duct composed of pancreatic duct cells.
Pancreatic stellate cells are located in the peri-acinar space, while centroacinar cells are
located in the transitional region between acinar and duct cells. Each acinar cell produces
and stores zymogen granules containing inactive digestive enzymes.
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1.1 Pancreatitis

Pancreatitis is an inflammatory disease predominantly thought to be caused by premature
activation of digestive enzymes, particularly trypsin, within the pancreatic acinar cell
leading to auto-digestion and tissue necrosis (Grady et al., 1998; Halangk et al., 2000;
Murtaugh and Keefe, 2015). However, studies have suggested a more complex etiology
for pancreatitis, as deletion of the trypsinogen gene in mice did not reduce pancreatitisassociated inflammation (Dawra et al., 2011), and activation of NF-kB signaling alone
was shown to be sufficient to induce acute pancreatitis (Baumann et al., 2007). This
suggests multiple pathways could be working in parallel to cause pancreatitis. The two
main types of pancreatitis are acute and chronic pancreatitis. While most cases of acute
pancreatitis are mild, there is significant morbidity and mortality associated with a subset
of severe acute pancreatitis cases (Koutroumpakis et al., 2017; Hazra et al., 2014).
Approximately 70-80% of acute cases have an attributable cause, which include alcohol
abuse, gall-stones, smoking, obesity and drug-hypersensitivity (Yadav et al., 2009;
Badalov et al., 2007; Chen et al., 2012; Lerch and Aghdassi, 2010; Guda et al., 2011).
Genetic factors play a role in pancreatitis; hereditary pancreatitis can be caused by
mutations in the human cationic trypsinogen (PRSS1) and serine protease inhibitor, Kazal
type 1 (SPINK1) genes (Teich et al., 2006; Witt et al., 2000), leading to premature
enzyme activation within the pancreatic acinar cell. Additionally, mutations in
chymotrypsin C (CTRC; Rosendahl et al., 2008) can lead to increased levels of active
trypsin enzyme, while mutations in carboxypeptidase A1 (CPA1; Witt et al., 2013) are
theorized to cause ER stress and are linked to pancreatitis. Lastly, mutations in the cystic
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fibrosis transmembrane conductance regulator (CFTR) gene (Bishop et al., 2005; Sharer
et al., 1998) can impair bicarbonate conductance and increase susceptibility to
pancreatitis. Hereditary forms of pancreatitis have an earlier onset and present initially as
acute episodes, before progressing to chronic pancreatitis (Howes et al., 2004; Girard et
al., 1981). Further, multiple episodes of acute pancreatitis (recurrent acute pancreatitis)
can be a risk factor for progression into chronic pancreatitis, especially in cases related to
alcohol or smoking (Lankisch et al., 2009; Sankaran et al., 2015).

Acute episodes of pancreatitis result in reversible damage to the pancreas which may be
resolved within approximately one week (Koutroumpakis et al., 2017). Conversely,
chronic pancreatitis (CP) is a progressive, long-term disease which can lead to
irreversible damage to the pancreas (Kloppel et al., 1993; Amman et al., 1996). CP is
characterized by an extensive inflammatory response, fibrosis and eventual endocrine and
exocrine insufficiency as the disease progresses (Kloppel et al., 1993; Amman et al.,
1996; Malka et al., 2000). The leading cause for CP includes alcoholism (Nikkola et al.,
2017; Irving et al., 2009) and biliary-related etiologies (Bertilsson et al., 2015; van Baal
et al., 2012), while smoking (Andriulli et al., 2010) can also play a role. There are
approximately 14,400 Canadians currently living with CP, and it is expected that more
than 2,000 new cases will be diagnosed each year (Teshima et al., 2012). Patients with
CP have a greatly reduced quality of life, with many patients becoming unemployed or
retiring earlier than planned due to decreased physical, social and/or emotional wellbeing
(Wehler et al., 2003). Diabetes mellitus is a common co-morbidity with CP; 20 years
after onset approximately 46% of chronic pancreatitis patients have been diagnosed with
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secondary diabetes (Type 3c diabetes mellitus) (Pan et al., 2016). Further, significant
mortality is associated with CP, with one long-term study identifying 44% mortality
within 10 years post-diagnosis (Yadav et al., 2011).

1.1.1 Animal models of pancreatitis

Animal models utilized to replicate acute human pancreatic injury includes hormonallyinduced pancreatitis (e.g. cerulein), administration of basic amino acids (L-arginine),
diet-induced pancreatitis (choline-deficient diet enriched with ethionine) and pancreatic
duct ligation (Lampel et al., 1977; Tani et al., 1987; Tani et al., 1990; Gilliland et al.,
1980; Mooren et al., 2003). The most commonly-used model is cerulein-induced
pancreatitis (CIP), in which supraphysiological doses of cerulein, a cholecystokinin
analogue, blocks enzyme secretion and leads to intracellular enzyme activation (Saluja et
al., 1999). Treatment with cerulein can be administered over a short time period (4-7
injections in one day), to mimic acute pancreatitis, or extended over a few weeks to
replicate the phenotype of recurrent pancreatitis (Elsasser et al., 1992). However, unlike
CP in humans, mouse pancreas regenerates following recurrent pancreatitis, reversing the
pancreatic damage (Elssasser et al., 1992). Long-term cerulein injections are still utilized
as a model of CP, as it recapitulates characteristics of the disease including extensive
fibrosis (Neuschwander-Tetri et al., 2000). This damage can be further amplified by
combination of cerulein with an additional sensitizer, such as ethanol (Deng et al., 2005)
or pancreatic duct ligation (Miyauchi et al., 2007).
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As a result of studies using animal pancreatic injury models, the progression of
pancreatitis has been characterized. Induction of pancreatic injury results in dysfunctional
calcium signaling with premature zymogen activation in acinar cells and activation of
inflammatory responses through release of TNF-a and the NF-kB pathway that can
further amplify enzyme activation (Krüger et al., 2000; Mooren et al., 2003; Sendler et
al., 2013; Dawra et al., 2011; Abdulla et al., 2011). Widespread apoptosis, necrosis and
edema is observed (Dawra et al., 2011). Acinar cell damage leads to the release of
chemokines and cytokines (including monocyte chemotactic protein, cytokine-induced
neutrophil chemoattractant, interleukin-6 (IL-6)) which can enhance pancreatic
inflammation and attract infiltrating immune cells, including neutrophils and
macrophages (Brady et al., 2002; Shimada et al., 2002). Accordingly, blocking
interleukin-6 (IL-6) or chemokine receptor CXCR2 attenuates inflammation in
pancreatitis models (Chao et al., 2006; Steele et al., 2015).

In CP, recurrent injury and inflammation promotes fibrosis, which is mediated through
activation of quiescent pancreatic stellate cells (PSCs) (Schneider et al., 2001; Mews et
al., 2002). Macrophages present in CP have been shown to secrete factors that promote
PSC-mediated fibrosis (Treiber et al., 2011). Further, PSCs can be activated by cytokines
that are shown to be upregulated in acute pancreatitis (including TNF-a and IL-6), and
TGF-b signaling can promote this process (Mews et al., 2002; van Laethem et al., 1996).
Once activated, PSCs can secrete extracellular matrix components, primarily collagen,
that contribute to fibrosis (Neushwander-Tetri et al., 2000).
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1.1.2 Regeneration & Acinar to ductal metaplasia (ADM)

Pancreatic damage from acute pancreatitis appears to subside within 1-2 weeks following
an episode of acute pancreatitis, indicating the regenerative capability of acinar tissue
(Siveke et al., 2008; Fendrich et al., 2009). A major event in the pancreatic response to
injury is acinar to ductal metaplasia (ADM), in which mature acinar cell markers (Mist1,
Amylase) are downregulated in acinar cells, while markers typically expressed in
pancreatic progenitor cells (sex-determining region Y box 9 (Sox9), pancreatic and
duodenal homeobox 1 (Pdx1), hepatocyte nuclear factor 6 (Hnf6)) or duct cells (keratin
19 (Ck19)) are upregulated (Karki et al., 2015; Pinho et al., 2011; Prevot et al., 2012;
Figure 1.2). This event could indicate trans-differentiation from acinar to duct cell, or
rather dedifferentiation of acinar cells to a progenitor-like state. ADM can be important
for regeneration, but the prolonged presence of ADM may sustain a loss of acinar identity
and provide susceptibility for oncogenic transformation (Halbrook et al., 2017; Shi et al.,
2013; Kopp et al., 2012). Several key factors have been identified that establish or
maintain acinar cell identity, including pancreas specific transcription factor, 1a (Ptf1a),
GATA-binding factor 6 (Gata6), nuclear receptor subfamily 5a2 (Nr5a2) and Mist1
(Hoang et al., 2016; Martinelli et al., 2013; von Figura et al., 2014b; Johnson et al.,
2004). Accordingly, loss of Nr5a2 or Mist1 increases susceptibility to pancreatic damage
and decreases the regenerative capability of tissue following injury (von Figura et al.,
2014b; Kowalik et al., 2007). Factors involved in mature acinar cell organization
(connexin 32 (Cx32), heat shock protein 27 (Hsp27)) can also influence response to
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pancreatic injury by altering acinar cell-cell communication and the acinar cell
cytoskeleton (Frossard et al., 2003; Kubisch et al., 2004).

Many signaling pathways required for ADM and subsequent pancreatic regeneration have
been identified, including epidermal growth factor receptor (EGFR) and downstream
KRAS activation of MEK/ERK signaling (Shi et al., 2013; Halbrook et al., 2017).
Overexpression of EGF is sufficient to drive ADM in a mouse model (Means et al.,
2003), and high levels of EGF ligands, including transforming growth factor a (TGF-a)
and amphiregulin (AREG), or EGFR have been observed in CP (Ardito et al., 2012).
Downstream of EGFR, inhibition of MEK signaling in a mouse model of CP was
sufficient to block ADM (Halbrook et al., 2017), supporting the requirement for EGFR
and MEK/ERK signaling in the occurrence of ADM.

Notch, Wnt and Hedgehog signaling all play a role in acinar regeneration following
injury, by regulating the differentiation status of acinar cells post-injury (Morris et al.,
2010a; Morris et al., 2010b; Siveke et al., 2008; Fendrich et al., 2009). Chromatin
remodeling proteins such as Enhancer of Zeste 2 (EZH2; Mallen St. Clair et al., 2012)
and B-cell specific Moloney murine leukemia virus insertion site 1 (BMI1; Fukuda et al.,
2012) are important in pancreatic regeneration, promoting a proliferative state. Many of
the pathways involved in pancreatic regeneration are also upregulated in pancreatic
cancer (including Kras, Wnt and Notch signaling) (Bailey et al., 2016). Accordingly, CP
is a risk factor for pancreatic cancer (Lowenfels et al., 1993; Raimondi et al., 2010). The
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relative risk for the development of pancreatic cancer in chronic pancreatitis is 13.3-fold,
with increased risk (69-fold) for those with hereditary pancreatitis (Raimondi et al.,
2010). Identification of pathways or events that link CP to pancreatic cancer would be
beneficial in limiting the progression of pancreatic disease.
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Pancreatic Injury

Acinar Cell
MIST1
Amylase
Carboxypeptidase

CK19
SOX9
PDX1
HNF6

Progenitor-like cell

CK19
SOX9
HNF6

Duct-like cell

MIST1
Amylase
Carboxypeptidase

Figure 1.2. Schematic of acinar-to-ductal metaplasia (ADM). In response to
pancreatic injury, acinar cells can undergo a process involving upregulation of pancreatic
progenitor (PDX1, SOX9, HNF6) and ductal markers (CK19) and decreased in mature
acinar cell markers (MIST1, Amylase, Carboxypeptidase), progressing towards a duct
cell phenotype.
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1.2 Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic cancer is a relatively rare but lethal disease, accounting for approximately
2.5% of new cancer cases in Canada last year, while causing 6% of cancer-related deaths
(Canadian Cancer Statistics, 2016). The most common type of pancreatic cancer is
pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 85% of total
pancreatic cancer cases (Ryan et al., 2014). Currently, the five-year survival rate for
PDAC is approximately 8% (Pancreatic Cancer Facts, 2016) because PDAC is typically
diagnosed in the late stages due to lack of early symptoms and biomarkers, and current
treatments are limited. Less than 20% of cases are treated surgically, as this treatment
option is typically reserved for cases that have not yet metastasized (Pancreatic Cancer
Facts, 2016). Available chemotherapeutic agents include a standard first-line treatment
gemcitabine (median survival 6.8 months), along with FOLFIRINOX, a combinatorial
treatment which leads to slight improvement in survival (median survival 11.1 months;
Conroy et al., 2011). Both treatments have limited efficacy long-term (Conroy et al.,
2011). One of the difficulties in treating PDAC is the presence of a dense stroma that
may support tumour progression and block effective treatments, consisting of a
heterogeneous population of cells including fibroblasts, pancreatic stellate cells and
inflammatory cells, and extra-cellular matrix (ECM) components (Neesse et al., 2015;
Hwang et al., 2009; Mahadevan et al., 2007).
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The etiology behind the majority of PDAC cases is unknown, with hereditary factors
accounting for approximately 10% of PDAC cases (Ryan et al., 2014). Families with a
history of pancreatic cancer are at higher risk, although the onset of familial pancreatic
cancer occurs only 5 years earlier than the average pancreatic cancer age of diagnosis
(Peterson et al., 2015). Genetic causes to account for increased familial risk have only
been identified in a subset of cases, including hereditary syndromes such as familial
breast cancer (BRCA2), Lynch syndrome and Peutz Jeghers syndrome (Klein et al.,
2004; Shi et al., 2009; Peterson et al., 2015; Matsubayashi et al., 2017). Patients with
mutation in the p16 gene (linked to familial atypical mole melanoma) have 17%
increased risk of developing pancreatic cancer, and mutations in the palladin gene,
encoding a protein involved in cytoskeletal organization, have been shown to play a role
in familial pancreatic cancer (Pogue-Geile et al., 2006). Aside from genetic factors,
lifestyle has been implicated in the etiology of pancreatic cancer, with proposed links to
cigarette smoking, high alcohol intake and increased body mass (Bosetti et al., 2012;
Wang et al., 2016; Aune et al., 2012).

1.2.1 Origin & acquired mutations in PDAC

One of the major controversies regarding pancreatic cancer is the cell of origin from
which PDAC arises. Precursor lesions for PDAC include pancreatic intraepithelial
neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMN) and mucinous
cystic neoplasms (MCNs; Hruban et al., 2007). Although PDAC demonstrates ductal
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characteristics, and these three precursor lesion types express ductal markers, lineage
tracing experiments in mouse models strongly support acinar cells as the cell of origin for
most PDAC cases (Kopp et al., 2012; Zhu et al., 2007; Ji et al., 2009; De La O et al.,
2008; Morris et al,. 2010b). These experiments demonstrated the capability of acinar cells
to transdifferentiate into duct cells, in both mouse models and cultured human acinar cells
(Strobel et al., 2007; Houbracken et al., 2011), and acinar cells can contribute to PanIN
lesions (Kopp et al., 2012). PanINs are non-invasive, neoplastic precursor lesions which
progress from low-grade PanIN1 to PanIN3, before reaching full-blown PDAC (Hruban
et al., 2004). PanIN1 lesions can accumulate over time and can be found in nonmalignant pancreata, while PanIN3 lesions are more typically associated with the
occurrence of invasive PDAC (Andea et al., 2003; Hruban et al., 2004).

A series of acquired mutations occurs as PDAC develops from its precursor lesions. The
earliest mutation is believed to occur in the KRAS gene, due to its presence in over 95%
of PDAC cases (Morris et al., 2010b), and activating KRAS mutation are observed in over
90% of early-grade PanIN1 lesions (Kanda et al., 2012). Other common early mutations
which increase in frequency throughout PDAC progression include CDKN2A (encoding
p16INK4A/p19ARF), TP53, and SMAD4, which are linked to cell cycle regulation, DNA
damage control and TGF-b signaling (Makohan-Moore et al., 2016; Waddell et al., 2015;
Jones et al., 2008). However, PDAC is a genetically heterogeneous disease, and genomic
sequencing has revealed additional mutations that occur at a lower frequency in subsets
of PDAC (Jones et al., 2008; Bailey et al., 2016). An extensive study by Bailey et al.,
2016 used these mutations to identify 10 common signaling pathways that may be
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mutated in PDAC, and classified PDAC into four subtypes accordingly. These pathways
included mutation in Notch signaling, SWI/SNF complexes, chromatin modifications and
DNA repair. PDAC is also characterized by large variations in chromosomal structure.
Waddell et al., (2015) demonstrated the presence of significant chromosomal
rearrangements and alterations which could disrupt gene expression in PDAC. The wide
range of acquired mutations and chromosomal instability in PDAC indicates the
importance of maintaining genomic stability to prevent PDAC initiation and progression.

1.3 KRAS

1.3.1 KRAS gene & protein

It has been estimated that approximately 30% of all cancers contain an activating RAS
mutation (Fernandez-Medarde et al., 2011). Within the specific RAS family, there are
three different classes of GTPases: HRAS, NRAS and KRAS. The members of the RAS
protein superfamily contain GTPase activity, and share a common catalytic G domain
with variability in their cellular processes and function (Paduch et al., 2001). Each RAS
protein (HRAS, NRAS, KRAS) is implicated in different cancer types, with KRAS
mutations found most frequently in epithelial tumours including lung, colon and
pancreas, as well as biliary tract, endometrial and ovarian cancers among others (Jančik
et al., 2010; Sohal et al., 2016; Schubbert et al., 2007). Pancreatic adenocarcinomas have
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the highest rate of oncogenic KRAS mutation, with over 95% of cases carrying mutations
(Morris et al., 2010b).

The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene is located on the short arm
of chromosome 12, and has two different isoforms; KRAS4A and KRAS4B due to
alternative splicing of exon 4. KRAS4B is more predominantly expressed in most human
cells (Jančik et al., 2010), and the majority of studies involving the KRAS protein focus
on the protein encoded by this isoform. The KRAS protein is a small 21kDa GTPase,
activated via GTP-binding and inactive when bound to GDP (Jančik et al., 2010). The
switch between active and inactive KRAS is mediated by two proteins, a guanine
nucleotide exchange factor (GEF) which promotes GTP binding, and a GTPase activating
protein (GAP) which promotes GTP hydrolysis (Jančik et al., 2010). Activating KRAS
mutations impede the ability of GAPs to induce GTP hydrolysis, maintaining KRAS in
an active state (Trahey et al., 1987). The most common amino acids for mutation include
residues G12, G13 and Q61 (Buhrman et al., 2010; Scheffzek et al., 1997). Stimulation of
KRAS activity by various growth factors or cytokines activates downstream signaling
pathways, regulating cellular processes including cell survival, proliferation and
differentiation (Crespo et al., 2000; Matallanas et al., 2006). External stimuli of KRAS
activity include inflammatory signals, as well as GPCR-mediated activation, including
EGFR signaling, through binding of EGFR ligands such as EGF and TGFa (Daniluk et
al., 2012; Harris et al., 2003; Logsdon et al., 2016).
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1.3.2 Downstream pathways of KRAS

Activation of oncogenic KRAS, and subsequent downstream signaling pathways, is an
important driving factor in PDAC initiation and progression (Collisson et al., 2012). The
canonical downstream target of KRAS is mitogen-activated protein kinase (MAPK)
signaling (Figure 1.3), in which the KRAS protein binds to serine/threonine kinase RAF
(MAPKKK), inducing translocation of the protein to the plasma membrane where it is
phosphorylated (Votjek et al., 1993; Marais et al., 1995). Active RAF then
phosphorylates MEK (MAPKK), which can then phosphorylate and activate downstream
proteins ERK1/2 (MAPK1/2; Crespo et al., 2000). Once phosphorylated, ERK proteins
can translocate to the nucleus and target a variety of downstream effectors, including
transcription factors such as JUN and ELK1 to regulate gene expression and cellular
proliferation levels (Crespo et al., 2000; Schubbert et al., 2007).

However, KRAS signaling is diverse and context-dependent, and influences many
downstream signaling pathways apart from MAPK signaling. Two major pathways
activated by KRAS are the phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositidedependent protein kinase 1 (PDK1)-Akt pathway and the RalGDS/p38 MAPK pathway.
The PI3K pathway is a well-characterized Ras-effector pathway known to mediate cell
survival (Castellano and Downward, 2011). Activation of PI3K leads to production of the
substrate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), that binds and activates PDK1
and Akt/PKB and lead to a series of downstream phosphorylation events (Castellano and
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Downward, 2011; Eser et al., 2013). In addition, KRAS activates exchange factors for
Ral GTPases (including Ral-GDS), leading to subsequent activation of Ral and
downstream phospholipase D (PLD; Lim et al., 2005). Other KRAS-mediated pathways
include RAC and RHO, and PLCe pathways (Schubbert et al., 2007; Eser et al., 2014;
Pylayeva-Gupta et al., 2011). Ras-regulation of Rho-GTPases has been demonstrated to
influence cytoskeleton regulation (Chen et al., 2003; Sahai et al., 2001), while Rasmediated PLCe signaling can activate protein kinase C (PKC) and regulate calcium
signaling (Song et al., 2001).
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Figure 1.3. MAPK signaling pathway downstream of active KRAS. Once activated
(by various stimuli including EGFR signaling), the KRAS GTPase induces a series of
phosphorylation events. Active KRAS phosphorylates RAF (mitogen activated protein
kinase kinase kinase; MAPKKK), which phosphorylates MEK (mitogen activated protein
kinase kinase; MAPKK) with subsequent phosphorylation of ERK (mitogen activated
protein kinase; MAPK). Phosphorylated ERK can translocate into the nucleus and target
specific transcription factors to alter gene expression and influence cellular proliferation.
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1.3.3 KRAS mutations in PDAC

The MAPK pathway activated by KRAS is vital in driving oncogenic PDAC (Collisson
et al., 2012; Collins et al., 2014), and studies demonstrate activation of endogenous or
transgenic oncogenic KRAS (KRASG12V or KRASG12D) in early pancreas leads to the
formation of PanINs and PDAC (Tuveson et al., 2004; Guerra et al., 2007; Grippo et al.,
2003; Hingorani et al., 2003). Furthermore, the use of models in which KRAS activity
can be turned on/off demonstrate the requirement of KRAS for both the initiation and
maintenance of PDAC (Collins et al., 2012). However, adult acinar tissue is less
susceptible than the developing pancreas to the induction of oncogenic KRAS (Huang et
al., 2014; Ji et al., 2009; Morris et al., 2010b), and additional factors such as injury or
acquired mutation are required to promote PanIN formation.

Daniluk et al., (2012) demonstrated that inflammatory stimuli in mice with oncogenic
KRASG12D lead to PanINs and a chronic inflammatory response, as opposed to minimal
effects from the same stimuli in wild-type mice. Furthermore, activation of
inflammatory-associated factor NFATc1and STAT3 co-operates with KRASG12D to
promote pancreatic cancer (Baumgart et al., 2014). This provides evidence to suggest
oncogenic KRAS makes acinar tissue more susceptible to the activation of inflammatory
pathways. Accordingly, the combination of KRAS mutation with pancreatic injury
greatly increases the amount of pancreatic damage. As opposed to wild-type mouse
models, mice with oncogenic KRAS activation that undergo acute pancreatic injury do
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not recover to the same extent, and form PanIN lesions (Collins et al., 2012; Morris et al.,
2010a). Acute pancreatitis accelerated the onset of PDAC in mice with KRASG12D
(Carriere et al., 2011), and induction of CP in KRASG12D mice was sufficient to promote
PDAC formation (Guerra et al., 2007). These studies demonstrate a co-operative role for
oncogenic KRAS activation and pancreatic injury in the occurrence of PDAC.

Oncogenic KRAS activation also promotes PDAC with loss of function in known tumour
suppressor genes, including p16Ink4a/p19Arf, Trp53 and Dpc/Smad4 (Bardeesy et al., 2006;
Hingorani et al., 2005; Kojima et al., 2007; Izeradjene et al., 2007). Furthermore,
combination of KRASG12D with loss of mature acinar cell factors such as Mist1, Nr5a2
and Gata6 promotes PanIN formation (Shi et al., 2013; von Figura et al., 2014b;
Martinelli et al., 2015). KRASG12D combined with upregulation of pathways associated
with a developmental or progenitor pancreatic phenotype, including Notch and Hippo
signaling, also promote PanIN formation (De La O et al., 2008; Zhang et al., 2014),
suggesting maintenance of acinar cell differentiation constrains KRAS-mediated
pancreatic disease. Lastly, oncogenic KRAS signaling can cooperate with the presence or
loss of chromatin remodeling proteins to promote PDAC, including members of the
polycomb protein family BMI1 and EZH2 (Bednar et al., 2015; Mallen-St. Clair et al.,
2012), as well as SWI/SNF chromatin remodeling protein BRG1 (von Figura et al.,
2014a).
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1.4 Chromatin Modifications & SWI/SNF Chromatin
Remodelers

1.4.1 Chromatin structure & modification

Modifications to chromatin can alter genomic stability and gene expression patterns and,
thus, there is increasing evidence for a role of chromatin remodelers in PDAC
suppression (Bailey et al., 2016; Wadell et al., 2015). The packaging of histones and
DNA into chromatin is an essential organization of genome, which regulates various
DNA processes including transcription, replication and repair. Chromatin consists of 147
DNA base pairs wrapped around an octamer of histone proteins (sets of histone variants
H2A, H2B, H3 and H4) to form a nucleosome core, which are connected by sections of
linker DNA (Luger et al., 1997; Richmond and Davey, 2003). Histone structure involves
basic N-terminal tails that protrude from the nucleosome unit, which undergo histone
modifications including acetylation, methylation and phosphorylation (Bannister and
Kouzarides, 2011; Luger at el., 1997). Histone tail acetylation is almost always associated
with increased chromatin accessibility and transcription, and conversely, deacetylation is
considered to be a mechanism of gene silencing (Kouzarides, 2007). Methylation
modifications are more specific to a particular arginine or lysine on a histone tail, can
occur as mono, di or trimethylation and, depending upon location, can be activating or
repressive marks (Kouzarides, 2007). For example, trimethylation of lysine 4 on histone
3 (H3K4me3) is shown to be an activating mark, while trimethylation of lysine 9 on
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histone 3 (H3K9me3) is repressive (Schuettengruber et al., 2007; Margueron et al., 2011;
Zhao et al., 2007).

Histone modifications help regulate nucleosome structure and recruit chromatin
remodeling enzymes dependent on the type of modification (Kouzarides, 2007). Once
recruited, chromatin remodelers utilize their ATPase activity to incorporate specific
histone variants, changing the accessibility and structure of the chromatin region
(Bushbeck et al., 2017). Non-canonical histone variants (such as histone 3.3) are viewed
as epigenetic marks that regulate genomic function, are synthesized throughout the cell
cycle and are not dependent on replication for deposition (Buschbeck et al., 2017).

1.4.2 SWI/SNF family of chromatin remodelers

Chromatin remodelers that contain an ATPase subunit are divided into subgroups,
including switching defective/sucrose non-fermenting (SWI/SNF), imitation switch
(ISWI), chromodomain, helicase, DNA binding (CHD/Mi2), SWI/SNF-related adenosine
triphosphate complex (SWRI) and inositol requiring 80 (INO80) ATPases, each with a
distinct structure and ATPase (Wilson et al., 2011; Mohrmann et al., 2005). These groups
utilize energy from ATP hydrolysis to rearrange chromatin structure by altering histoneDNA interaction and sliding nucleosomes along DNA (Mohrmann et al., 2005; Vignali et
al., 2000). The first SWI/SNF complex was characterized in yeast (Stern et al., 1984;
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Neigeborn and Carlson, 1984), with homologous complexes identified in Drosophila and
mammals (Papoulos et al., 1998; Wang et al., 1996). The SWI/SNF complexes are large
and consist of 9-12 subunits (Smith et al., 2003; Wang et al., 1996), and the composition
of proteins can vary. In humans, there are two ATPase subunits which can be
incorporated: BRM(SMARCA2) or BRG1(SMARCA4) (Bultman et al., 2000; Wang et
al., 1996).

SWI/SNF complexes have many diverse regulatory roles in the genome, and mutations in
SWI/SNF complexes have been found in a number of cancer types. A survey of 44
exome/genome sequencing studies identified SWI/SNF subunits mutations in 19.6% of
all human tumours (Kadoch et al., 2013). BRG1 mutations have been detected in lung
cancer and multiple human cancer cell lines, including those lines derived from prostate,
lung, breast and pancreas (Marquez-Vilendrer et al., 2016; Wong et al., 2000). Mutations
in other subunits of SWI/SNF complexes have been correlated to cancer, including
ARID1A in breast and clear cell ovarian cancers (Jones et al., 2011; Takao et al., 2017),
and PBRM1, mutated in 41% of clear cell renal cancers (Varela et al., 2011). A study of
esophageal squamous cell carcinomas demonstrated cases with inactivating mutation in
ARID1A, BRG1 and ATRX among others, suggesting SWI/SNF mutation may be an early
occurrence in this cancer type (Nakazato et al., 2010). This thesis will focus specifically
on SWI/SNF chromatin remodelling protein ATRX, and investigate the potential role of
ATRX loss in promoting pancreatic disease.
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1.4.3 a-thalassemia/mental-retardation, X-linked protein (ATRX)
syndrome

The ATRX syndrome, which includes the unusual co-presentation of intellectual
disability and a-thalassemia in male children from three unrelated families, was first
defined in 1981 (Weatherall et al., 1981). Patients with ATRX syndrome present with a
spectrum of clinical symptoms, including severe cognitive defects, facial abnormalities
and a-thalassemia (Gibbons et al., 1995). Additional symptoms may include urogenital
and skeletal abnormalities, generalized hypotonia from birth, short stature and
gastrointestinal issues (Gibbons et al., 2000a). As an X-linked disorder, ATRX syndrome
occurs predominantly in males. Phenotypically normal carrier females who are
heterozygous for ATRX mutation show skewed X chromosome inactivation (XCI) for the
X-chromosome carrying the mutation (Gibbons et al., 1992). Mutations in the ATRX gene
causing ATRX syndrome are typically missense and lead to hypomorphic function of the
ATRX protein (Gibbons et al., 2008). It appears that complete loss of ATRX function is
lethal, as mouse models carrying germ-line null Atrx mutations/deletions do not produce
viable embryos (Garrick et al., 2006). It was shown that Atrx deletion in the 8-16 cell
stage of the mouse embryo caused defects in the formation of extraembryonic
trophoblast, causing lethality within 9 days of Atrx ablation (Garrick et al., 2006).
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1.4.4 ATRX gene & protein structure

The ATRX gene is 36 exons long, and spans approximately 300 kb on the X-chromosome
(Picketts et al., 1996). There are two alternatively spliced transcripts of approximately
10.5 kb, which are different at their 5' ends due to alternative splicing of exon 6 (Villard
et al., 1997). ATRX is ubiquitously expressed in all tissue types, with high levels of
expression in the brain (Gecz et al., 1994). The two isoforms of ATRX give rise to
proteins of 265 kDa or 280 kDa. The ATRX protein belongs to the SNF2 subgroup of the
SWI/SNF protein family (Picketts et al., 1996). It contains two functionally conserved
domains; an N-terminus ADD (ATRX-DNMT3-DNMT3L) domain and a C-terminus
SWI/SNF ATPase domain (Figure 1.4; Argentaro et al., 2007). The ADD domain is
named based on its sequence homology with a family of de novo DNA
methyltransferases, and is highly cysteine-rich with two different types of zinc finger
motifs (Argentaro et al., 2007). The first motif is a zinc finger, and the second is an
atypical plant homeodomain (PHD) zinc finger (Argentario et al., 2007; Gibbons et al.,
1997). The C-terminus of the ATRX protein contains a SWI/SNF ATPase domain with
helicase activity involved in chromatin remodeling (Mitson et al., 2011). The presence of
mutations leading to ATRX syndrome are most often found in one of these two
conserved domains, with approximately 49% of ATRX syndrome mutations in the ADD
domain, and 30% in the SWI/SNF ATPase domain, indicating the functional importance
of each domain (Gibbons et al., 2008). There is also a conserved, truncated isoform of the
ATRX protein called ATRXt, caused by a failure to splice exon 11 of the ATRX gene
(Garrick et al., 2004). The resultant protein lacks the C-terminal SWI/SNF domain,
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suggesting it has reduced functionality compared to the full-length ATRX protein
(Garrick et al., 2004).
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Figure 1.4. Schematic of ATRX protein. The ATRX protein contains two function
domains; a N-terminal ADD (ATRX-DNMT3-DNMT3L) domain and a C-terminal
SWI/SNF ATPase domain. Within the ADD domain, there are two zinc finger motifs;
GATA-1like C2C2 and atypical plant homeodomain (PHD). Interaction sites between
ATRX and death-domain associated protein (DAXX) or heterochromatin protein-1 (HP1)
are indicated in pink.
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1.4.5 Binding Partners & ATRX cellular localization

ATRX is a nuclear protein, associated with the nuclear matrix during interphase (Berube
et al., 2000). Nuclear localization of ATRX can be altered with ATRX mutation, leading
to a more diffuse nuclear pattern of staining (Cardoso et al., 2000). During the metaphase
stage of mitosis, ATRX localizes to condensed chromosomes following a
phosphorylation event in association with heterochromatin protein-1 (HP1) (Berube et al.,
2000).

The ability of ATRX to bind to DNA through its N-terminal domain was demonstrated in
vitro (Cardoso et al., 2000), and it can interact with and bind RNA (Sarma et al., 2014).
ATRX is often localized to areas of heterochromatin and largely repetitive regions of
DNA, including telomeres and centromeres (McDowell et al., 1999; Law et al., 2010;
Lewis et al., 2010). The localization of ATRX to heterochromatin is believed to be
mediated through its N-terminal ADD domain (McDowell et al., 1999;), as well as the
interaction between ATRX and HP1. The ADD domain binds to histone 3 (H3) tails with
the specific histone trimethylation mark H3K9me3, a marker of heterochromatin,
especially in the absence of H3K4 methylation (Dhayalan et al., 2011). HP1 is thought to
stabilize this ATRX recruitment event, as mutation in the HP1 binding site on the ATRX
protein reduces its heterochromatic localization (Figure 1.4; Eustermann et al., 2011). An
additional interaction occurs specifically in neurons, where methyl-CpG binding protein
(MECP2) associates with ATRX to recruit it to heterochromatin (Nan et al., 2007).
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Importantly, the localization of ATRX is not solely confined to heterochromatic regions;
ATRX can bind to intergenic regions and gene bodies, especially those containing
tandem repeat sequences (Law et al., 2010).

In addition to HP1, a major protein partner of ATRX is death domain-associated protein
(DAXX). The DAXX protein was demonstrated using immunoprecipitation assays to be
in complex with ATRX, and responsible for targeting ATRX to promyelocytic leukemia
PML nuclear bodies (Xue et al., 2003; Tang et al., 2004). DAXX works in complex with
ATRX to mediate incorporation of histone variant 3.3 (H3.3) at pericentric
heterochromatin and telomeres in a replication-independent manner (Drane et al., 2010;
Lewis et al., 2010). Once H3.3 is incorporated, it can be targeted for K9 trimethylation to
produce a heterochromatic state and maintain stability of the telomere (Udugama et al.,
2015).

1.4.6 Regulation of gene expression and DNA methylation

Loss of ATRX leads to decreased expression of the a-globin gene cluster located on
chromosome 16 (Wilkie et al., 1990), suggesting it may act as a transcriptional regulator.
The interaction of ATRX with the Su(var)3-9, enhancer of zeste, and trithorax (SET)
domain of the EZH2 protein, part of the Polycomb Repressive Complex 2 (PRC2),
provides further evidence of a regulatory role for ATRX in gene expression (Cardoso et
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al., 1998). PRC2 is a histone methylase complex, associated with gene silencing and
repressive chromatin (Margueron and Reinberg, 2011). ATRX can recruit PRC2 to Xist
RNA during X chromosome inactivation, as well as other PRC2 targets throughout
genome (Sarma et al., 2014). ATRX also associates with the inactivated X-chromosome
(Baumann and De La Fuente, 2009), and is required to maintain gene silencing at
interstitial heterochromatin and imprinted regions (Voon and Wong, 2015; Kernohan et
al., 2010). Finally, ATRX influences DNA methylation throughout the genome, as
patients with ATRX syndrome show patterns of altered DNA methylation (Gibbons et al.,
2000b). DNA methylation analysis performed on blood samples of ATRX patients
demonstrated differentially DNA methylated regions, including pericentromeric and
telomeric regions in patients with ATRX mutation (Schenkel et al., 2017). Taken
together, these studies strongly suggest a role for ATRX in altering gene expression.
Further, ATRX regulates additional processes aside from gene regulation, including DNA
replication, repair and cell cycle processes.

1.4.7 Cell cycle regulation

The effects of ATRX loss on mitosis in proliferating cells are evident in several different
tissue types, including neuroprogenitor cells, Sertoli cells of the testes, skeletal muscle
and forelimb mesenchyme (Bagheri-Fam et al., 2011; Bérubé et al., 2005; Huh et al.,
2012; Ritchie et al., 2008). ATRX knockdown in HeLa cells led to prolonged
prometaphase to metaphase transition, due to impaired chromosome congression to the
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spindle equator (Ritchie et al., 2008). ATRX knockdown reduced cohesion between sister
chromatids, and caused chromosome segregation defects during mitosis (Ritchie et al.,
2008). Increased apoptosis was observed in Atrx-null mouse neuroprogenitor cells,
cultured from E12.5 embryos containing a conditional neuroprogenitor-specific Atrx
deletion, suggesting mitotic defects from ATRX loss may contribute to cell death in the
developing forebrain (Berube et al., 2005; Ritchie et al., 2008; Seah et al., 2008). Cell
cycle impairment was observed in skeletal muscle development, where ATRX loss led to
delayed S phase progression and mitotic spindle defects in myoblasts (Huh et al., 2012),
and in Atrx-null Sertoli cells of the testes, causing prolonged G2 to M phase transition and
increased apoptosis (Bagheri-Fam et al., 2011). These studies demonstrate a role for
ATRX in maintaining genomic stability in actively dividing cells. Interestingly, although
Atrx deletion in the forelimb mesenchyme lead to brachydactyly and increased cell death
(Soloman et al., 2013b), loss of ATRX in chondrocytes or osteoblasts had minimal
effects on cartilage and skeletal development (Soloman et al., 2013a; Soloman et al.,
2013b). Within the exocrine pancreas, the role of ATRX in pancreatic development has
not yet been characterized. ATRX has also been implicated in regulating meiosis, as loss
of ATRX led to defects in chromosome alignment along the meiotic spindle during
metaphase II (De La Fuente et al., 2004). These authors proposed a role for ATRX in
binding to centromeric heterochromatin, to mediate proper chromosome alignment during
meiosis.
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1.4.8 DNA replication & repair

The previous studies cited support a clear link between ATRX loss and replicative stress
in proliferating cells, suggesting ATRX is required to maintain genomic stability during
replication. More recently, studies have defined a role for ATRX in preventing
replication fork stalling, which lead to collapse and double-stranded DNA breaks (DSBs)
if unresolved by DNA repair responses (Branzei and Foiani, 2010; Clynes et al., 2014;
Huh et al., 2016). It has been proposed that ATRX prevents the formation of DNA
secondary structures during replication that lead to these stalled replication forks
(Gibbons et al., 2010). ATRX binds to tandem-repeat sequences (Law et al., 2010),
which are often guanine-rich (G-rich) sequences and have the propensity to form
secondary DNA structures called G-quadruplexes (G4; Duquette et al., 2004). Gquadruplexes are abnormal and form potential obstacles for normal DNA processes
including DNA replication and transcription (Rizzo et al., 2009; Levy et al., 2014) and
stabilization of these G4 structures induces replicative stress (Rizzo et al., 2009;
Rodriguez et al., 2012). Approximately 50% of ATRX binding sites indicated by ChIP
were predicted to form G4 structures, and electrophoretic mobility shift assays indicated
ATRX interacted with G4 DNA in vitro (Law et al., 2010). ATRX is believed to
incorporate H3.3 into G-rich sequences to prevent G4 DNA formation and allow the
proper passage of transcriptional machinery (Gibbons et al., 2010; Levy et al., 2014). In
support of this mechanism, Atrx-null neuroprogenitor cells had increased susceptibility to
treatment with a G4-stabilizing ligand (Watson et al., 2013).
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In addition to the prevention of replication fork stalling, ATRX may also play a role in
recruiting DNA repair complexes to resolve stalled forks. ATRX and the MRE11RAD50-NBS1 (MRN) complex interact to facilitate replication fork restart and repair
double stranded breaks (Clynes et al., 2014; Leung et al., 2013), indicating a role for
ATRX in DNA repair. Loss of ATRX increases DNA damage in mouse ES cells (Clynes
et al., 2014), and enhance sensitivity to a variety of DNA damaging agents (Conte et al.,
2012). An apparent link exists between loss of ATRX and activation of p53, with the
occurrence of p53-mediated apoptosis in Atrx-null neuroprogenitors and myoblasts
(Conte et al., 2012; Watson et al., 2013; Huh et al., 2012).

1.4.9 Telomere maintenance & Alternative Lengthening of Telomeres
(ALT)

In mouse embryonic stem cells, ATRX localized to telomeres with H3.3 during
replication in the S-phase, and RNAi knockdown of Atrx led to telomere dysfunction
(Wong et al., 2010). Deletion of Atrx in mouse neuroprogenitor cells lead to increased
telomere fusion, and other telomeric defects including deletions and duplications (Watson
et al., 2013). These studies indicate a role for ATRX-mediated telomere maintenance,
which is supported by the upregulation of the alternative lengthening of telomeres (ALT)
pathway that occurs with ATRX loss (Lovejoy et al., 2012; Clynes et al., 2015; Bower et
al., 2012).
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ALT is a mechanism through which telomeres maintain their length independent of
telomerase enzyme by using homologous recombination (HR) (Bryan et al., 1997;
Dunham et al., 2000). ALT is believed to be utilized in 10-15% of cancers but varies
based on cancer type (Heaphy et al., 2011b). A role for ATRX in suppression of the ALT
pathway has been well-established, although loss of ATRX alone is not sufficient to drive
ALT (Clynes et al., 2014). A study of 22 ALT-positive cell lines demonstrated 90% were
negative for ATRX (Lovejoy et al., 2012), while use of somatic cell hybrids
demonstrated a correlation between ATRX loss and presence of the ALT pathway
(Bower et al., 2012). Ectopic ATRX expression reversed the ALT phenotype, and
ATRX-mediated suppression of the ALT pathway was dependent on DAXX (Clynes et
al., 2015). These findings suggest a mechanism in which ATRX stabilized telomeric
regions using H3.3 incorporation, preventing the formation of secondary DNA structures
leading to double-stranded DNA breaks and subsequent HR.

1.4.10 Malignancies involving ATRX mutation

Given the previously described roles of ATRX in cell cycle processes, DNA replication
and repair and telomere maintenance, it is not unexpected that ATRX mutations have been
implicated in several types of cancer. One of the first reported cases of acquired, somatic
ATRX mutations occurred in patients with a-thalassemia myelodysplasia syndrome
(ATMDS; Gibbons et al., 2003). Additional studies identified ATRX mutations in several
types of diffuse gliomas, including astrocytomas and glioblastomas (Jiao et al., 2012;
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Kannan et al. 2012; Wiestler et al., 2013). Mutation frequency in adult gliomas is
distributed evenly across the ATRX gene, and typically result in frameshifts or nonsense
mutations (Jiao et al., 2012). These mutations often co-occur with TP53 or IDH1
mutations, and are correlated to the presence of ALT (Jiao et al., 2012; Kannan et al.,
2012; Schwartzentruber et al., 2012). Assessment of ATRX in glioma can be prognostic
(Pekmezci et al., 2017; Karsy et al., 2017), and ATRX loss has been indicated as a
favourable prognostic factor in a subset of astrocytic tumours (Wiestler et al., 2013). In
cases of paediatric glioblastoma, in which ATRX is mutated in approximately 30% of
patients, mutations are typically found near the carboxy-terminal helicase domain
(Schwartzentruber et al., 2012). ATRX mutations have also been implicated in paediatric
osteosarcomas (Ellison et al., 2014; Lovejoy et al., 2012), and melanomas (Qadeer et al.,
2014). ATRX has been suggested to act as a negative regulator of histone variant macro
H2A1.2, which is linked to melanoma progression (Ratnakumar et al., 2012). In contrast
to many other cancer types, ATRX is over-expressed in colorectal cancer cell lines
(Athwal et al., 2015), and may cooperate with DAXX to incorporate the histone variant
CENP-A into chromatin, altering the normal chromatin state.

1.4.11 ATRX mutation in pancreatic neuroendocrine tumours
(PNETs)

ATRX mutations have been implicated in pancreatic neuroendocrine tumours (PNETs), a
rare type of tumour with demonstrated chromosomal instability (Hu et al., 2010).
Genomic analysis on 68 cases of PanNETs identified mutations for ATRX or DAXX in
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43% of samples, while 44% contained mutations in the MEN1 tumour suppressor gene
(Jiao et al., 2011). In the majority of ATRX-mutated cases, deletions or insertions and
nonsense mutations in the ATRX gene lead to loss of the ATRX protein (Jiao et al., 2011).
Mutations in ATRX and DAXX are almost always mutually exclusive, indicating they
perform similar functions in a tumour-suppressive role (Jiao et al., 2011; Yachida et al.,
2012). Loss of DAXX or ATRX was strongly correlated to the ALT phenotype, and the
presence of chromosomal instability in PNETs (Heaphy et al., 2011a; Marinoni et al.,
2014). Conflicting reports exist on the prognosis of DAXX/ATRX mutations in PNETs,
and their effect on long-term survival is unclear. However, a recent study by Singhi et al
(2017) demonstrated that DAXX/ATRX loss in PanNETs resulted in higher rates of
metastasis and a poor survival rate. Within the exocrine pancreas, there is currently
limited information regarding ATRX loss and PDAC.

1.5 Rationale, Hypothesis & Objectives

Pancreatic ductal adenocarcinoma (PDAC) is a rare but lethal disease of the exocrine
pancreas, with a five-year survival rate of less than 6%. Constitutively activating KRAS
mutation (KRASG12D) is present in greater than 95% of PDAC cases, but KRAS mutation
alone is insufficient to drive PDAC progression. Additional factors, such as acquired
somatic mutation or pancreatic injury, are required to promote disease progression.
Previous studies have implicated a role for chromatin remodelers, including BMI1 (von
Figura et al., 2014a), in constraining KRASG12D-mediated PDAC. However, the role of
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chromatin remodeling protein ATRX has not yet been characterized in the context of the
exocrine pancreas. In other tissues, ATRX is shown to play a role in many cellular
processes including gene regulation, cell cycle progression, DNA replication and
telomere maintenance. In the exocrine pancreas, ATRX loss could alter these processes,
influencing acinar cell function or response to pancreatic insult, including pancreatitis or
oncogenic KRAS activation.

It is hypothesized that inducible deletion of Atrx will increase the susceptibility of
acinar cells to pancreatic injury or KRASG12D oncogenic transformation. Two main
objectives were completed to address this hypothesis. First, mice with acinar cell-specific
inducible Atrx deletion underwent recurrent pancreatic injury to determine the role of
ATRX in the acinar cell response to injury. Second, acinar cell-specific Atrx deletion was
combined with oncogenic KRASG12D activation in mice to determine the role of ATRX in
constraining KRAS-mediated oncogenic transformation. This work defines a novel role
for ATRX in disease progression in the exocrine pancreas, and provides further insight
into acinar cell factors that influence susceptibility to pancreatic disease.
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Chapter 2

2

Methods

2.1 Animal Care and Cre Induction

All mouse experiments were approved by the Animal Care and Use Committee at the
University of Western Ontario (Protocol #2017-001). Male and female C57Bl6 mice
expressing creERT from the Mist1 locus (Mist1creERT/+; Shi et al., 2013) were crossed
with mice harboring an Atrx allele with the 18th exon flanked by loxP sites (Berube et al.,
2005), producing male (Mist1creERT/+AtrxflΔ18/y) and female (Mist1creERT/+AtrxflΔ18/fl Δ18)
mice, collectively referred to as Mist1creERT/+AtrxflΔ18. Control mice were considered mice
heterozygous for the creERT allele (Mist1creERT/+) or wildtype for Mist1 (Mist1+/+), and
were collectively referred to as Mist1creERT/+, as previous literature and extensive work in
our laboratory has established no difference in phenotype between mice wild-type or
heterozygous for Mist1 expression (Karki et al., 2015; unpublished data).

Mist1creERT/+AtrxflΔ18 mice were also crossed to mice containing an inducible form of
oncogenic KRAS (loxP-STOP-loxP (LSL)-KRASG12D), to produce Mist1creERT/+LSLKRASG12DAtrxflΔ18 mice (referred to as MKA). In 2-4 month old mice, tamoxifen (SigmaAldrich, St. Louis, MO, USA) was administered through oral gavage (2 mg/mouse), three
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times over five days. Mice were monitored for a period of 60 days from first tamoxifen
gavage, and body weight was measured weekly.

2.2 Cerulein Induced Pancreatitis (CIP)

To induce recurrent pancreatic injury, 60 days following tamoxifen gavage, control
(Mist1creERT/+) and Mist1creERT/+AtrxflΔ18 mice (see Table 2.1 for n values) were given
intraperitoneal injections of cerulein (Sigma-Aldrich, St. Louis, MO, USA, 75 µg/kg
body weight), twice daily for 11 days, followed by a three-day recovery period. Saline
injections were used as a control. Mice were weighed daily throughout the pancreatitis
protocol. Three days following cessation of cerulein treatment, mice were sacrificed and
pancreatic tissue was collected for analysis.

2.3 Serum Amylase Assay

Immediately following euthanasia, blood was collected from mice through intra-cardiac
puncture and placed on ice for 30 minutes. Blood samples were centrifuged at 3,000 rpm
at 4°C for 15 minutes, and supernatant (blood serum) collected. Levels of serum amylase
were determined using the Phadebas amylase test (Magle Life Sciences, Cambridge,
MA, USA), according to kit instructions. Briefly, serum samples were diluted in buffer
(0.9% NaCl, 0.2% bovine-serum albumin [BSA], 20 mM CaCl2), placed in 4 mL distilled

41

water and incubated at 37ºC for 5 min. A Phadebas tablet was placed in each tube,
incubated at 37ºC for 15 min, and then 1 mL of 0.5M NaOH was added to each sample.
Samples were centrifuged at 1500 rpm for 5 min, and absorbance of the supernatant was
measured at 620 nm, using the Ultrospec 2100 pro UV/Visible spectrophotometer
(Thermo Fisher Scientific, Fremont, CA, USA).

2.4 Histological Quantification and Analysis

Mouse pancreata (taken from the head-mid region of the pancreas) were fixed overnight
in 4% formalin, washed with phosphate-buffered saline (PBS) for 24 hours, and placed in
70% ethanol prior to embedding in paraffin. Paraffin tissue sections (5 µm thickness)
were stained using standard H&E, Alcian Blue or Masson’s Trichrome stain (ab150686;
Abcam Inc.) protocols. The Alcian Blue kit used was specific to pH 2.5 to target all
acidic mucins (Mucin Stain; ab150662; Abcam Inc.). Sections were imaged using the
Aperio CS2 Digital Scanner and Aperio ImageScope software (Leica Biosystems
Imaging Inc, San Diego, CA, USA). Levels of pancreatic damage in recurrent pancreatic
injury and KRASG12D models were assessed using a grading scale based on three factors fibrosis, inflammation and presence of acinar to ductal metaplasia. Tissue sections were
scored on a scale from 0 – 4. Representative images and descriptions of each score can be
found in Supplementary Figure S1; Supplemental Table S1.
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Total tissue area was quantified using the Fiji software (Schindelin et al., 2012), and area
of damage was quantified as a percentage of total area. Total number of pancreatic
lesions (between 0-800, ranging from ADM to PanIN grade 3) were quantified and
classified into the following categories; ADM, PanIN grade 1, PanIN grade 2, PanIN
grade 3, based on morphological characteristics including cell shape (cuboidal or
columnar), presence of mucin accumulation, nuclear atypia, pseudostratification and
papillary or cribriform structure (see Supplemental Figure S5 for examples).

2.5 Immunohistochemistry (IHC) and Immunofluorescence
(IF)

For immunohistochemical analysis (IHC), paraffin tissue sections (5 µm thickness) were
stained using the ABC staining system (Santa Cruz Biotechnology Inc., Dallas, TX, sc2018/2017) or the VectaStain ABC HRP kit with ImmPACT DAB Peroxidase (HRP)
Substrate (Vector Laboratories, PK-4001/SK-4105, Brockville, ON, CA) according to kit
instructions, counterstained with hematoxylin and coverslipped using Permount
Mounting Medium (Thermo Fisher Scientific). Cleaved-caspase 3 staining was
completed using the Ventana Discovery Ultra XT autostainer (Ventana Medical Systems
Inc, Tuscon, AZ). Slides were imaged at 20x and 40x magnification using light
microscopy (Leica DFC450 microscope camera on the Leica DM5500B microscope;
Leica Microsystems Ltd., Wetzlar, Germany) with Leica LAS V4.4 software. Primary
antibodies used are specific to ATRX (diluted in 1.5% mouse blocking serum in PBS,
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1:100; Santa Cruz Biotechnology Inc.), carboxypeptidase (CPA; 1:1000; Abcam), SOX9
(1:500; Abcam Inc., Cambridge MA), PDX1 (1:1000; Abcam Inc.), Ki67 (1:500; Abcam
Inc.) and cleaved caspase 3 (1:100; Cell Signaling Technology, Danvers, MA).

For immunofluorescence (IF), mouse pancreata were frozen in cryomatrix and sectioned
into 6 µm sections. Tissue sections were kept at -20°C until processing, then warmed to
room temperature and fixed in 4% formalin for 10 min, followed by 0.1% Triton in PBS
for 10 min. Slides were placed in blocking solution (0.1% Triton X-100 in 5% BSA in
PBS) for 30 min, and incubated in primary antibody overnight at 4°C. Following three 5
min PBS washes, slides were incubated in secondary antibody for 1 h at room
temperature (RT), washed with PBS, stained with 4',6-diamidino-2-phenylindole (DAPI)
and mounted with Permafluor mountant (Thermo Fisher Scientific). Slides were imaged
at 40x magnification using fluorescence microscopy (Leica DFC365 FX camera on the
Leica DM5500B microscope; Leica Microsystems Ltd.), and Leica LAS V4.4 software.
Primary antibodies used are specific to ATRX (diluted in blocking solution, 1:100; Santa
Cruz Biotechnology Inc.), MIST1 (1:500; Pin et al., 2000), b-catenin (1:500; Sigma),
Insulin (1:500; Sigma), or gH2AX (1:200; Santa Cruz Biotechnology Inc.). Secondary
antibodies used include anti-rabbit FITC and anti-mouse FITC (1:250; Jackson
ImmunoResearch, West Grove, PA).
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2.6 Protein Isolation & Western Blot Analyses

Mouse pancreata were flash frozen in liquid nitrogen immediately following dissection,
then homogenized in a protein isolation buffer consisting of: 50 mM Tris pH 7.2, 5 mM
MgCl2, 1 mM CaCl2, 10 mM DTT, 1% Nonidet P-40, DNAse (100 units/ml), RNAse (50
µg/ml), 1 mM PMSF, 30 mM NaF, 2 mM Na3VO4 and protease inhibitors leupeptin,
aprotinin and pepstatin (5 µg/ml each). Once homogenized, samples were sonicated for
20 seconds, centrifuged at 14,000 rcf for 5 min at 4°C, and supernatant was retained.
Protein concentrations were quantified using the Bradford protein assay (Bio-Rad,
Hercules, CA). Isolated protein was resolved by SDS-PAGE in 10% acrylamide gels and
transferred to a PVDF membrane (Bio-Rad) at 200 mA for 90 minutes. Blots were
blocked with 5% non-fat dried milk (NFDM) and incubated in primary antibody
overnight at 4°C in 5% NFDM (total ERK1/2 and SOX9 antibodies were incubated in
5% BSA-0.1% Tween20). Following incubation, blots were washed in PBS-0.1%
Tween20, 4x for 5 min, then incubated in secondary antibody (anti-rabbit HRP, 1:10,000;
Jackson Labs, Bar Harbor, ME) in 5% NFDM for 1 h at room temperature. Blots were
washed 4x for 5 min in PBS-0.1% Tween20, and developed using Western Lightening
chemiluminescence substrate (Perkin Elmer, Waltham, MA). Blots were visualized using
the VersaDoc system with Quantity One 1-D analysis software (Bio-Rad). Primary
antibodies used were specific for SOX9 (1:500; Abcam), CPA (1:1000; Abcam), amylase
(1:1000; Abcam) and p44/42 MAPK (ERK1/2) (1:2500, Cell Signaling Technology).
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2.7 TUNEL Assay

To assess apoptosis, 6 µm pancreatic sections were fixed in 4% formalin for 10 min at
room temperature, washed with PBS for 3x for 5 min and permeabilized with 0.1%
Triton X-100 in 0.1% sodium citrate in PBS, for 2 min on ice. Using the In Situ Cell
Death detection kit (Roche, Laval, QC, CA), slides were labelled with the TUNEL
reaction mixture for 1 h at 37°C. Following three PBS washes, slides were stained with
DAPI and mounted with Permafluor mountant (Thermo Fisher Scientific). The number
TUNEL-positive cells was quantified using 7 random fields of view from each mouse,
and calculated as percentage of TUNEL positive cells compared to DAPI counts.

2.8 Quantitative real-time PCR

RNA was isolated from splenic pancreatic tissue using TRIZOL (Invitrogen, Carlsbard,
CA, USA), and the SV Total RNA Isolation system (Promega, Madison, WI). Briefly, a
small piece of pancreatic tissue (>2 cm wide) was immediately placed in 5 mL TRIZOL
and homogenized for 30 sec. The solution was mixed after the addition of 1 mL
chloroform, incubated at 4°C for 3 min and centrifuged (4°C) for 15 min. The
supernatant was removed and washed 4x with 70% ethanol. DNase was added to the
RNA for 15 min at RT, followed by DNase stop solution, 2 washes, and elution of RNA
in RNase-free water. 1 µg of RNA was reverse-transcribed using ImPromII Reverse
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transcriptase (Sigma). Quantitative RT-PCR (qRT-PCR) was carried out using primers
specific to the Mist1 gene:
Fwd: 5' GTGGTGGCTAAAGCTACGTG 3'
Rev: 5' GACTGGGGTCTGTCAGGTGT 3'
and the GoTaq PCR Mastermix system (Promega, Madison, WI, USA) using an ABI
Prism 7900HT Sequence Detection System and SDS 2.2.1 software (Applied Biosystems,
Foster City, CA, USA).

2.9 Statistical Analysis

Data was analyzed for significance using an unpaired, two-tailed T-test or two-way
ANOVA with Tukey’s post-hoc test with GraphPad Prism 6 software. Values are
depicted as means ± standard error of the mean (SEM). Significance is considered
p<0.05.
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3

Results

To determine if ATRX affected the phenotype of mature acinar cells, mice with exon 18
in the Atrx gene flanked by loxP sites (Berube et al., 2005) were mated to mice
expressing an inducible cre recombinase from the Mist1 locus (Shi et al., 2013). Since
ATRX is an X-linked gene, male mice are referred to as Mist1creERT/+ AtrxflΔ18/y and
female mice are Mist1creERT/+ AtrxflΔ18/ flΔ18. These mice will collectively be referred to as
Mist1creERT/+ AtrxflΔ18 hereafter (Figure 3.1). The Mist1 gene (driving creERT) is
expressed in serous exocrine cells of the pancreas but not duct or centroacinar cells of the
pancreas (Pin et al., 2000). Tamoxifen induced cre recombination was induced in 2-4
month-old mice and ATRX accumulation assessed 7, 35 or 60 days after dosing (Figure
3.2A, B). Immunofluorescent (IF) analysis indicated 98% of the acinar cells were ATRXnegative 7 days following tamoxifen gavage, demonstrating efficient Atrx deletion. Two
months post-gavage, 98% of cells remained negative for ATRX, indicating mature acinar
cells can survive without ATRX expression (Figure 3.2B). IF co-staining for ATRX with
insulin, a marker of pancreatic islets, demonstrated ATRX expression in islets, while
surrounding acinar tissue was largely devoid of ATRX expression (Figure 3.2C). ATRX
expression remained visible in other non-acinar cell types, including ductal, centroacinar
and interstitial cells (Figure 3.2A, C; white arrows) based on nuclear morphology and
tissue location.
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Since ATRX can affect mitosis and DNA repair (Ritchie et al., 2008; Clynes et al., 2014;
Conte et al., 2012; Leung et al., 2013), the levels of DNA damage and acinar cell death
were examined 60 days following tamoxifen treatment. Assessment of gH2AX
accumulation showed an increased presence in DNA double stranded breaks in
Mist1creERT/+AtrxflΔ18 mice, suggesting increased DNA damage with loss of ATRX
(Supplemental Figure S2; Figure 3.2D). Furthermore, TUNEL analysis demonstrated
increased acinar cell apoptosis (Supplemental Figure S2; Figure 3.2E), suggesting
ATRX loss caused mild injury or cell stress in a subset of acini. Assessment of MIST1
expression levels, a marker of the mature acinar cell which is down-regulated during
injury (Fazio et al., submitted) indicated decreased MIST1 accumulation by IF, and a
trend towards a reduction in Mist1 mRNA in Mist1creERT/+ AtrxflΔ18 pancreatic tissue
(Figure 3.2F). Combined these results suggest the loss of Atrx results in a mild
pancreatic injury, which may make the pancreas susceptible to additional stress.
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Figure 3.1. Schematic of Atrx deficient mouse model. Cre-recombination events driven
by expression from the Mist1 promoter produces deletion of exon 18 of the Atrx gene, in
combination with expression of oncogenic KRASG12D in 2-4 month old mice.
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Figure 3.2. Mature acinar cells do not require ATRX for survival, but ATRX loss
induces low levels of pancreatic damage. (A) Immunofluorescence (IF) for ATRX
expression in pancreatic tissue 7 (n=8), 35 (n=3), and 60 (n=4) days following tamoxifen
gavage. White arrows indicate ATRX expression in non-acinar cell types, based on nuclei
morphology. (B) Efficiency of Atrx deletion was quantified as percentage of acinar cells
lacking ATRX expression. (C) IF for ATRX and insulin, a marker of pancreatic islets,
demonstrates acinar-specific knockout of ATRX expression in Mist1creERT/+AtrxflΔ18 mice.
White arrows indicate ATRX expression in non-acinar cell types. (D) Quantification of
gH2AX-positive acinar cells in control (Mist1creERT/+) and Mist1creERT/+AtrxflΔ18 mice
shows increased presence of double-stranded DNA breaks in cells lacking ATRX
(Mist1creERT/+, n=7; Mist1creERT/+AtrxflΔ18, n=11; * denotes p=0.004). (E) Quantification of
TUNEL-positive apoptotic cells in control (Mist1creERT/+) and Mist1creERT/+AtrxflΔ18 mice
demonstrate increased acinar cell death with loss of ATRX (Mist1creERT/+, n=9;
Mist1creERT/+AtrxflΔ18, n=10; * denotes p=0.0006). (F) IF staining for MIST1 protein
expression indicates decreased MIST1 in Mist1creERT/+AtrxflΔ18 mice, as supported by
qRT-PCR (Mist1creERT/+, n=4; Mist1creERT/+AtrxflΔ18, n=6; p=0.058 indicated by t-test). In
all cases, bars represent means ± standard error.
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3.1 Loss of ATRX increases susceptibility to recurrent
pancreatic injury

To determine if the mild injury observed in Mist1creERT/+AtrxflΔ18 mice affects the
pancreatic response to recurrent injury, Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice were
subjected to recurrent pancreatic injury for 11 days (Figure 3.3A) and then allowed to
recover for three days. Upon dissection, no gross morphological differences were
observed between Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice (data not shown), and no
significant difference in body weight was observed between groups, either prior to or
throughout pancreatic injury (Figure 3.3B). Assessment of serum amylase levels, a
marker of pancreatitis severity, revealed no differences between groups (Figure 3.3C).
However, histological analysis showed marked differences between these two groups.
Cerulein-treated Mist1creERT/+ mice show limited differences when compared to salinetreated controls, with the presence of intra-acinar edema (Figure 3.4A). This was
unexpected but suggests that the cerulein dosing regime was suboptimal to produce levels
of damage typically observed in recurrent pancreatic injury protocols, and resulted in
minimal damage to the tissue. Conversely, cerulein-treated Mist1creERT/+AtrxflΔ18 mice
show increased inflammation, potential acinar-to-ductal metaplasia (ADM; Figure 3.4A;
Table 3.1), and increased levels of fibrosis, as indicated by Trichrome stain analysis
(Figure 3.4B; Table 3.1). Surprisingly, this damage appears to be more extensive in
Mist1creERT/+AtrxflΔ18 female mice (Table 3.1).
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Figure 3.3. No alteration in body weight and serum amylase levels between ceruleintreated Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice. (A) Experimental timeline for
recurrent pancreatic injury model in 2- 4 month old congenic Mist1creERT/+ or
Mist1creERT/+AtrxflΔ18 mice. (B) Percent change in body weight of mice during prior to and
during recurrent CIP (red arrow indicates cessation of treatment). (C) Serum amylase
levels in mice (n=4-5 for each group) three days following cessation of recurrent CIP
treatment. Bars represent mean ± standard error. No significant difference in body weight
or amylase levels was observed between genotypes.
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Figure 3.4. Loss of ATRX increases susceptibility to recurrent pancreatic injury. (A)
Representative H&E staining of saline or cerulein (CIP) treated Mist1creERT/+ and
Mist1creERT/+AtrxflΔ18 mice three days following cessation of pancreatic injury.
Mist1creERT/+ CIP-treated mice show intra-acinar edema relative to saline-treated control
mice. CIP-treated Mist1creERT/+AtrxflΔ18 mice demonstrate increased pancreatic damage,
fibrosis and putative ADM relative to CIP-treated Mist1creERT/+ mice (black arrows
indicate the presence of inflammatory cells in CIP-treated Mist1creERT/+AtrxflΔ18 mice).
Similar analysis suggests that Mist1creERT/+AtrxflΔ18 female mice show more extensive
injury. Representative scale bar is indicated for each panel. (B) Representative Trichrome
stain of Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 pancreatic tissue, three days following
cessation of CIP treatment, indicating the level of fibrosis present throughout the tissue.
Mist1creERT/+AtrxflΔ18 mice exhibit increased fibrosis based on Trichrome staining
(presence of blue indicates fibrotic areas, indicated by black arrow), to a greater extent in
female Mist1creERT/+AtrxflΔ18 mice.
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Table 3.1. Morphometric analysis of pancreatic tissue following recurrent
pancreatic damage
Male

Fibrosis
Inflammation

Female

Mist1creERT/+ (5)

Mist1creERT/+ AtrxflΔ18
(5)

Mist1creERT/+ (4)

Mist1creERT/+ AtrxflΔ18
(5)

0

0

0

1.4

0.2

1.4

0.75

2.4

ADM

0

0.6

0

1.2

Total

0.2±0.2

2.0±0.45

0.75±0.25

5.0±1.1

(#) – indicates n value; see methodology for scoring. Histopathological assessment of pancreatic damage, as
indicated by three factors; fibrosis, inflammation and the presence of ADM. Scores are represented on a grading
scale from 0 – 4. There are increased levels of pancreatic damage in cerulein-treated Mist1creERT/+ AtrxflΔ18
mice compared to other groups.
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To determine if increased damage observed in Mist1creERT/+AtrxflΔ18 mice following injury
correlates with increased levels of apoptosis, cleaved caspase-3 levels in acinar tissue
were quantified using IHC (Figure 3.5). Results demonstrated no significant differences
in levels of apoptosis between genotypes or genders. Similarly, assessment of
proliferation in cerulein-treated Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice revealed no
significant differences (Figure 3.6), indicating a change in apoptosis or proliferation was
likely not a primary factor through which loss of ATRX altered the response to pancreatic
injury (Figure 3.6).

ADM are identified by a reduction in differentiated acinar cell markers (including
amylase, carboxypeptidase (CPA)), and a concomitant increase in progenitor/ductal
markers (including SOX9) that are not typically expressed in acinar tissue (Karki et al.,
2015; Pinho et al., 2011; Prevot et al., 2012). In wild-type pancreatic tissue, the
transcription factor SOX9 is expressed only in ductal and centroacinar cells (Prevot et al.,
2012). Previous studies showed SOX9 upregulation in both ADM and advanced
pancreatic lesions (Kopp et al., 2012; Prevot et al., 2012). Three days following cessation
of pancreatic injury, histological analysis suggested increased instances of ADM in
Mist1creERT/+AtrxflΔ18 mice relative to Mist1creERT/+ mice. To confirm the increased ADM
within Mist1creERT/+AtrxflΔ18 mice following injury, acinar tissue was examined for the
presence of amylase, carboxypeptidase or SOX9. In corroboration with the histological
analysis, IHC showed a consistent and significant decrease in CPA staining in female
Mist1creERT/+AtrxflΔ18 mice, in response to chronic injury (Figure 3.7A), which was not
observed in Mist1creERT/+ mice or Mist1creERT/+AtrxflΔ18 male mice. Western blot analyses
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confirmed decreased CPA in Mist1creERT/+AtrxflΔ18 cerulein-treated mice of both genders,
compared to cerulein-treated control mice (Figure 3.7B). Conversely, Mist1creERT/+
cerulein-treated mice exhibited an upregulation of CPA compared to saline-treated
controls. Amylase levels are also upregulated in cerulein-treated Mist1creERT/+ mice but
not in cerulein-treated Mist1creERT/+AtrxflΔ18 mice (Figure 3.7B).

IHC analysis for SOX9 showed increased nuclear staining in Mist1creERT/+AtrxflΔ18
pancreatic tissue following CIP treatment (Figure 3.7A), although no increase in total
Sox9 levels was observed by Western blot analyses (Figure 3.7B). Taken together, this
data suggests loss of ATRX increases the sensitivity of acinar cells to recurrent
pancreatic injury, leading to upregulation of progenitor markers, consistent with
increased tissue damage and ADM.

60

Figure 3.5. Acinar-specific apoptosis is not significantly altered between Mist1creERT/+
and Mist1creERT/+AtrxflΔ18 mice during recurrent CIP. (A) IHC analysis reveals
variation in cleaved caspase 3 staining in Mist1creERT/+ (n=4 for both saline and ceruleintreated groups) and Mist1creERT/+AtrxflΔ18 mice (male Mist1creERT/+AtrxflΔ18 saline n=4,
remaining groups n=5) of both genders (black arrows indicate acinar cells positive for
caspase-3). Images demonstrate areas of high staining in cerulein-treated
Mist1creERT/+AtrxflΔ18 mice, although there is variability present within the tissue. (B)
Quantification of percentage of acinar cells positive for cleaved caspase 3 expression.
Bars represent mean ± standard error.
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Figure 3.6. Acinar cell proliferation is not significantly altered between Mist1creERT/+
and Mist1creERT/+AtrxflΔ18 mice following CIP. (A) Representative IHC for Ki67
accumulation, indicating variation in the number of acinar cells undergoing proliferation
in Mist1creERT/+ (n=3) and Mist1creERT/+AtrxflΔ18 mice (n=3), following recurrent pancreatic
injury. Black arrows indicate Ki67-positive acinar cells. Images demonstrate areas of
high Ki67 staining present within tissue, although there is variability throughout the
tissue. (B) Quantification of percentage of acinar cells positive for Ki67 expression. Bars
represent mean ± standard error.
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Figure 3.7. Mist1creERT/+AtrxflΔ18 pancreatic tissue shows decreased digestive enzyme
accumulation, and increased SOX9 staining. (A) IHC analysis for carboxypeptidase
(CPA) and SOX9 in Mist1creERT/+ or Mist1creERT/+AtrxflΔ18 mice, three days following
cessation of recurrent CIP treatment. CPA staining was decreased in female
Mist1creERT/+AtrxflΔ18 mice (acinus is indicated by a dotted line). Conversely, SOX9
staining was increased in both male Mist1creERT/+AtrxflΔ18 and female Mist1creERT/+AtrxflΔ18
tissue (black arrows). Higher magnification images show specific SOX9 staining. (B)
Representative Western blot analysis for CPA and amylase indicated increased digestive
enzymes specifically in Mist1creERT/+ mice, while Mist1creERT/+AtrxflΔ18 mice demonstrated
decreased enzymes. Total ERK1/2 (tERK1/2) was used as a loading control.
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3.2 The loss of ATRX enhances oncogenic KRAS-induced
pancreatic injury in female mice

If loss of Atrx increases the potential for ADM, this would suggest that
Mist1creERT/+AtrxflΔ18 mice would be more susceptible to oncogenic KRAS activation, as
maintenance of the acinar phenotype is shown to be important in constraining KRASinduced transformation (Shi et al., 2013; von Figura et al., 2014b; Martinelli et al., 2015).
Further, chronic forms of pancreatic injury, which demonstrate sustained ADM, are a
significant risk factor for the development of PDAC (Malka et al., 2002; Lowenfels et al.,
1993). To assess the potential for increased damage with oncogenic KRAS,
Mist1creERT/+AtrxflΔ18 mice were mated to mice containing an inducible form of oncogenic
KRAS (LSL-KRASG12D) to generate Mist1creERT/+LSL-KRASG12DAtrxflΔ18 mice (hereafter
referred to as MKA mice) (Figure 3.8A). Control female mice included mice that are
heterozygous (Mist1creERT/+AtrxflΔ18/x) or wild-type (Mist1creERT/+Atrxx/x) for the Atrx allele,
and will collectively be referred to as Mist1creERT/+ mice. Similarly, female mice with
KRAS activation that were heterozygous for Atrx expression (Mist1creERT/+LSLKRASG12DAtrxflΔ18/x), or wild-type for Atrx expression (Mist1creERT/+LSL-KRASG12DAtrxx/x)
are collectively referred to as female Mist1creERT/+LSL-KRASG12D mice.

Cre-recombinase-mediated induction of KRASG12D and/or deletion of Atrx was performed
in 2- 4 month old congenic Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSLKRASG12D and MKA mice, which were followed for two months prior to sacrifice (Figure
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3.8A). Again, efficient Atrx deletion was confirmed using IHC (Figure 3.8B). There was
no significant difference observed in body weight between groups (Figure 3.8C), and
assessment of serum amylase levels revealed no differences (Figure 3.8D). Initial gross
examination of the pancreas in situ demonstrated variability in the appearance of
pancreatic tissue between groups, with the presence of enlarged spleens in both female
Mist1creERT/+LSL-KRASG12D and MKA mice, and evidence of edema in female MKA mice
(Supplemental Figure S3).
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Figure 3.8. Combined Atrx deletion with oncogenic KRAS activation does not alter
body weight of mice. (A) Experimental timeline for tamoxifen gavage in 2-4 month old
congenic Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-KRASG12D (denoted as LSLKRASG12D) and MKA mice. (B) IHC revealed ATRX expression in acinar (black arrow)
and duct (red arrow) cells of Mist1creERT/+ mice. In Mist1creERT/+AtrxflΔ18 mice, ATRX
expression was limited to islets (open arrow) and duct cells (red arrow). (C) Change in
body weight (%) of mice (both genders) following Atrx deletion +/- oncogenic KRAS
activation showed no significant differences (Mist1creERT/+AtrxflΔ18 denoted as AtrxflΔ18,
Mist1creERT/+LSL-KRASG12D denoted as LSL-KRASG12D). Points are represented as mean
weight ± standard error. (D) Serum amylase levels in mice (n=3-8 in each group), two
months following Atrx deletion +/- oncogenic KRAS activation. Bars represent mean ±
standard error.
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Previous reports suggest that on its own, activation of oncogenic KRASG12D in mature
acinar cells is insufficient to cause widespread pancreatic damage (Morris et al., 2010b; Ji
et al., 2009). Accordingly, Mist1creERT/+LSL-KRASG12D mice demonstrated normal
pancreatic morphology, with few instances of ADM or more progressive PanIN lesions
(Figure 3.9). However, MKA mice demonstrated increased in levels of pancreatic
damage, but exclusively in females (Figure 3.9). Female MKA mice also exhibited
increased levels of inflammation and fibrosis, along with disruption to the normal acinar
cell organization (Figure 3.9; Table 3.2), relative to all other groups. Interestingly, male
MKA mice exhibited little to no pancreatic damage, even to a lesser extent than male
Mist1creERT/+LSL-KRASG12D mice.
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Figure 3.9. Female Mist1creERT/+AtrxflΔ18 mice show increased sensitivity to oncogenic
KRAS activation. Representative H&E images of pancreatic tissue from male and
female Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-KRASG12D and MKA mice 60
days after tamoxifen treatment. Increased tissue damage is observed in MKA females.
Insets show higher magnification.
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Table 3.2. Morphometric analysis of pancreatic tissue 60 days after activation of
KRASG12D and loss of Atrx
Mist1creERT/+

Mist1creERT/+AtrxflΔ18

Mist1creERT/+
G12D
LSL-KRAS

Mist1creERT/+LSLG12D
flΔ18
KRAS
Atrx

Male
(8)

Female
(5)

Male
(8)

Female
(5)

Male
(7)

Female
(10)

Male
(10)

Female
(6)

Fibrosis

0

0

0

0

1

0.7

0

1.83

Inflammation

0

0

0.14

0.33

1

1

0.2

2.17

ADM

0

0.2

0

0

1.57

1.5

0.4

3

Total

0±0

0.2±0.2

0.14±0.14

0.33±0.21

3.57±1.8

3.2±1.4

0.6±0.27

7±1.57

(#) – indicates n value; see methodology for scoring. Histopathological assessment of pancreatic damage, as
indicated by three factors; fibrosis, inflammation and the presence of ADM. Scores are represented on a grading
creERT/+
G12D
flΔ18
scale from 0 – 4. There are increased levels of pancreatic damage in female Mist1
LSL-KRAS
Atrx
mice
compared to other groups.

74

Trichrome staining for fibrosis indicated the increased fibrotic areas in female MKA
pancreatic tissue (Figure 3.10A; Supplementary Figure S3), while Alcian blue staining,
which is characteristic of metaplastic lesions in this tissue, confirmed the presence of
PanIN lesions (Figure 3.10A). The total number of lesions (ranging from ADM to
PanIN2) was quantified within each group, and demonstrated a significant increase in the
number of lesions within female MKA mice (Figure 3.10C), although quantification of
total area of damage (expressed as a percentage of total tissue area) was not significant
(Figure 3.10B).

To determine the progression of PanIN formation within acinar tissue, Mist1creERT/+LSLKRASG12D and MKA mice were assessed for the presence of each lesion type (ranging
from ADM to PanIN2); the percentage of pancreatic lobules containing at least one
instance of each lesion type was quantified (Representative images of each in
Supplemental Figure S5). Mist1creERT/+LSL-KRASG12D and MKA mice both exhibited
ADM, however the incidence of PanIN1 was increased 2.5-fold in female MKA mice
(Figure 3.10D). Furthermore, increased instances of PanIN2 were observed within
female MKA mice (Figure 3.10D). These results demonstrated that Atrx loss increased
sensitivity to KRASG12D and promoted increased damage, characteristic of chronic
pancreatitis, and PanIN lesion formation, within a relatively short two-month time period.
Furthermore, it appeared that damage was exclusive to the female MKA mice.
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Figure 3.10. Increased pancreatic damage and progression in PanIN lesions were
evident in female MKA mice. (A) Representative images of Alcian blue stain or
Trichrome stain (indicator of fibrosis) confirms duct metaplasia (open arrow) and fibrosis
(closed arrow) in areas of damage within female MKA mice. (B) Quantification of total
lesion area (relative to total area of acinar tissue), and (C) total number of lesions within
each group (* denotes p<0.05). Bars represent mean % of damage ± standard error.
Mist1creERT/+AtrxflΔ18 are denoted as AtrxflΔ18, and Mist1creERT/+LSL-KRASG12D mice are
denoted as LSL-KRASG12D. Female MKA mice demonstrate increased number of lesions,
as well as a trend towards increased area of pancreatic damage. (D) Average percentage
of lobules containing at least one instance of ADM to PanIN 2. Mist1creERT/+LSLKRASG12D mice are denoted as LSL-KRASG12D. Results demonstrate female MKA mice
show increased levels of PanIN 1 and 2 lesions.
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Similar to the recurrent pancreatic injury model, examination of SOX9 staining revealed
no significant differences between Mist1creERT/+ and Mist1creERT/+AtrxflΔ18 mice, nor
increased staining in Mist1creERT/+LSL-KRASG12D and male MKA mice (Figure 3.11A).
However, female MKA mice showed increased staining for SOX9 in the nucleus (Figure
3.12A, Figure 3.12A) that was widespread in both pancreatic lesions and acinar tissue
adjacent to areas of damage, suggesting acinar cells with increased SOX9 may be primed
to undergo the ADM process. Again, Western blot analyses revealed no differences in
global SOX9 levels (Figure 3.12C). To confirm ADM, transcription factor PDX1 was
assessed. PDX1 is a factor essential for pancreatic development with low levels of
expression in mature acinar tissue, but upregulated in ADM and PanIN lesions (Roy et
al., 2016). Increased PDX1 staining was observed in female MKA acinar tissue adjacent
to areas of damage and in pancreatic lesions (Figure 3.12B, Figure 3.12B) compared to
all other groups, suggesting upregulation of ADM factors occurs in acinar tissue prior to
ADM.
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Figure 3.11. Loss of ATRX alone does not alter SOX9 and PDX1 staining in acinar
cells. IHC for SOX9 (A) and PDX1 (B) in control (Mist1creERT/+) and mice lacking
ATRX (Mist1creERT/+AtrxflΔ18) revealed no differences in staining in either gender.
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Figure 3.12. Loss of ATRX combined with oncogenic KRAS lead to increased SOX9
and PDX1 staining in acinar tissue only in female MKA mice. IHC for SOX9 (A) and
PDX1 (B) in Mist1creERT/+LSL-KRASG12D (denoted as LSL-KRASG12D) and MKA mice of
both genders revealed increased acinar cell staining specifically in female MKA mice
(black arrows), and expression in putative ADM (open arrows). (C) Representative
western blot analyses for SOX9 reveals no significant differences between groups. Total
ERK1/2 (tERK1/2) was used as a loading control.
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3.3 Acinar cells with loss of ATRX contribute to KRASmediated pancreatic lesion formation

To determine if loss of ATRX alters proliferation in acinar cells, a largely post-mitotic
tissue, IHC for Ki67 was performed (Figure 3.13A). Compared to mice with ATRX
expression, Mist1creERT/+AtrxflΔ18 mice demonstrated increased numbers of Ki67+ acinar
cells, indicating an increased number of cells are undergoing active cell division (Figure
3.13). These results suggest that loss of ATRX results in increased acinar cell
proliferation.

To further examine the manner in which ATRX loss may influence the development of
pancreatic damage, ATRX staining was assessed within pancreatic lesions of
Mist1creERT/+LSL-KRASG12D and MKA mice of both genders. Lesions present within
Mist1creERT/+LSL-KRASG12D mice were mostly ATRX positive (Figure 3.14A, B). Female
Mist1creERT/+LSL-KRASG12D mice heterozygous for ATRX expression (Mist1creERT/+LSLKRASG12DAtrxflΔ18/x) demonstrated 58±17% ATRX-positive lesions. However, lesions
within male and female MKA mice exhibited 82±7% and 73±10% ATRX-negative
lesions, respectively, with 17.5±7% and 27±10% ATRX-positive lesions (Figure
3.14A,B). From these results, it appears that while PanIN formation can occur
independently of ATRX expression, ADM and PanINs are forming mostly from ATRXnegative cells. Interestingly, a pattern similar to the variable ATRX staining in female
MKA mice is observed with Ki67 staining (Figure 3.14A).
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Figure 3.13. Acinar cell proliferation is increased following the loss of ATRX. (A)
Representative IHC indicated an increase in acinar-cell Ki67 staining in mice lacking
ATRX, compared to control (Mist1creERT/+) mice (black arrow). (B) Quantification of
Ki67+ acinar cells indicated a trend towards increased acinar cell proliferation with loss
of ATRX in both genders, which did not increase in the presence of oncogenic KRAS.
Mist1creERT/+AtrxflΔ18 are denoted as AtrxflΔ18, and Mist1creERT/+LSL-KRASG12D mice are
denoted as LSL-KRASG12D.
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Figure 3.14. Acinar cells with loss of ATRX contribute to KRAS-mediated
pancreatic lesion formation. (A) IHC for Ki67 in Mist1creERT/+LSL-KRASG12D (denoted
as LSL-KRASG12D) and MKA mice indicated positive Ki67 cells in male and female MKA
mice (open arrows). ATRX expression was evident in PanINs in female Mist1creERT/+LSLKRASG12D mice (black arrow), while female MKA revealed both ATRX+ and ATRXcells within the PanINs (* indicates lesion with some ATRX+ cells; ** indicates lesion
with no ATRX+ cells), confirming cells with ATRX loss can contribute to ADM and
PanIN lesions. (B) Quantification of lesions with ATRX+ or ATRX- cells in
Mist1creERT/+, Mist1creERT/+, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSL-KRASG12D and MKA
mice. Bars represent mean % ± standard error.
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Chapter 4

4

Discussion

4.1 Overall Findings

This work defines a novel role for chromatin remodeler ATRX within the adult exocrine
pancreas, utilizing a cre-loxP mouse model to inducibly ablate ATRX expression in
pancreatic acinar cells. Loss of ATRX within acinar tissue does not produce
morphological changes or impact short-term survival, indicating ATRX is not required
for mature acinar cell viability. However, ATRX loss caused modest increases in DNA
damage, proliferation and apoptosis, indicating mild injury may be induced in acinar
tissue with loss of ATRX.

When exposed to recurrent pancreatic injury, the loss of ATRX resulted in greater extent
of pancreatic damage, demonstrating increased levels of fibrosis, inflammation and
ADM. Furthermore, combination of ATRX loss with oncogenic KRAS activation
produced extensive pancreatic damage indicative of chronic pancreatitis. Increased
fibrosis and inflammation was observed, as well as the presence of PanIN lesions up to
PanIN grade 2. Interestingly, this damage was exclusive to the female population of mice,
suggesting a gender-specific effect of ATRX. Taken together, this work demonstrates
that ATRX loss enhances the susceptibility of acinar tissue to pancreatic injury, either by
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experimentally induced pancreatitis or oncogenic KRAS activation, through gender
specific mechanisms. This pancreatic injury has the potential to progress into PDAC in
females, and thus ATRX loss in humans may act in co-operation with KRAS to promote
PDAC.

4.2 General Discussion

4.2.1 Role of ATRX in pancreatic injury

Three days following recurrent cerulein-induced pancreatitis, mice lacking ATRX had
increased pancreatic damage, with a fibrotic response, inflammatory cell infiltration and
instances of ADM, which are not observed in the control mice. Differences in levels of
circulating serum amylase were not observed between control and Mist1creERT/+ AtrxflΔ18
mice, however this is not unexpected as mice were allowed to recover for three days prior
to sacrifice. There are at least two possible ways in which ATRX loss can lead to
increased damage; either the loss of ATRX causes more extensive initial injury, or ATRX
loss interferes with the regenerative process.

If the former option is true, this suggests that the initial damage in Mist1creERT/+ AtrxflΔ18
mice requires a longer recovery time for complete regeneration to occur, explaining the
difference in levels of damage between control and Mist1creERT/+ AtrxflΔ18 mice, 3 days
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post-injury. Previous work in our lab using an acute pancreatitis protocol indicated
relatively similar amounts of damage in control and Mist1creERT/+ AtrxflΔ18 mice,
immediately following injury. However, repeated episodes of acute pancreatitis
(recurrent pancreatitis) in this study could amplify the amount of initial damage observed
with ATRX loss. In support of this, the downregulation of Mist1 gene expression
observed in mice lacking ATRX suggests an initial susceptibility to pancreatic injury, as
loss of Mist1 prior to injury has been shown to increase necrosis and tissue damage in
acute cerulein-induced pancreatitis (Kowalik et al., 2007). To determine if ATRX loss
does result in worse initial damage after recurrent injury, assessment of pancreatic tissue
immediately following injury would allow for comparison between initial damage in
control and Mist1creERT/+AtrxflΔ18 mice.

Conversely, it is possible that the loss of ATRX delays or impairs the regenerative
process following injury. Previous studies have identified roles for chromatin remodeling
proteins in regeneration after pancreatitis, including EZH2 and BMI1, members of the
polycomb repressive complex family of proteins (Fukuda et al., 2012; Mallen-St. Clair et
al., 2012). In both studies, acinar regeneration was compromised with loss of the
chromatin remodeling protein, due to decreased proliferation. In this study, ATRX loss in
non-injured acinar tissue increased DNA damage (indicated by positive gH2AX staining)
and acinar cell apoptosis in a small subset of acinar cells, potentially inducing these
effects in the relatively few acinar cells that are actively undergoing cell division. This
would be consistent with previous roles of ATRX in mitotically active tissue, where
ATRX has been shown to maintain genomic stability and regulate cell cycle processes
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(Ritchie et al., 2008; Watson et al., 2013; Clynes et al., 2014; Huh et al., 2012). It is
possible that these defects become more wide-spread once injury is induced, and
increased DNA damage and/or replicative defects may provide a barrier to acinar tissue
regeneration. Interestingly, assessment of apoptosis and proliferation markers in ceruleintreated mice revealed variable results, suggesting that this is not the primary mechanism
through which ATRX loss promotes damage.

Another possible mechanism of pancreatic damage could include increased inflammation
with loss of ATRX, preventing proper regeneration from occurring. A typical
inflammatory response in pancreatitis includes the infiltration of leukocytes and
macrophages, causing secretion of inflammatory cytokine tumour necrosis factor a
(TNFa) and interleukin-6 (IL-6), as well as other factors that promote pancreatic stellate
cell activation and subsequent fibrosis (Sendler et al., 2013; Shimada et al., 2002; Treiber
et al., 2011; Mews et al., 2002). Assessment and/or inhibition of these cytokines and their
downstream pathways (NF-kB, JAK/STAT signaling) in this pancreatitis model could
further characterize a relationship between ATRX loss and inflammation. Future
experiments could also include assessment of additional long term time points, 1- 2
weeks following injury, to determine if ATRX loss has delayed or fully blocked
regeneration from occurring.
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4.2.2 SOX9 Regulation

Following pancreatic injury or KRAS activation, mice lacking ATRX exhibit increased
instances of ADM, which contain obvious nuclear staining for SOX9, a progenitor cell
marker expressed in ADM and early PanIN lesions. This is expected, as SOX9
expression as a driving factor in ADM has been well-established previously (Kopp et al.,
2012; Prevot et al., 2013). Further, SOX9 staining was also observed in acinar tissue
surrounding ADM, suggesting SOX9 precedes the morphological change from acinar cell
to ADM. Interestingly, Western blot analyses of SOX9 did not demonstrate differential
SOX9 levels, contradicting the immunohistochemical analyses of SOX9. This finding is
aligned with work from our collaborating lab of Dr. Arthur Brown, in which they
observed no changes in SOX9 mRNA levels, but altered IHC staining of SOX9. There
are a couple potential reasons for this difference: post-translational modification of SOX9
or factors influencing antibody binding and/or specificity. Transcriptional regulation of
SOX9 expression is downstream of several signaling pathways, including NF-kB (Sun et
al., 2013), Wnt/b catenin (Larsimont et al., 2015) and MAPK signaling (Ling et al.,
2011). However, modifications of the SOX9 protein have also been demonstrated,
including phosphorylation (Huang et al., 2000) and acetylation which prevented nuclear
translocation of the SOX9 (Bar Oz et al., 2016). It is possible that post-translational
modification of SOX9 alters the nuclear localization of this protein, leading to changes in
staining intensity in IHC. Alternatively, these modifications or other alterations to SOX9
protein conformation could prevent antibody binding in immunohistochemistry, which
would not be an obstacle in the denatured environment of Western blot analyses.
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4.2.3 Role of ATRX in combination with oncogenic KRAS activation

My results indicate that Atrx deletion or oncogenic KRAS mutation alone in adult acinar
tissue does not lead increased pancreatic damage. In accordance with previous literature
(Grippo et al., 2003; Guerra et al., 2007), activating KRAS mutations required an
additional acquired mutation, in this case ATRX loss, to promote pancreatic damage.
Interestingly, this study demonstrates a gender specific pancreatic phenotype, in which
ATRX loss/KRAS activation leads to extensive damage within the female cohort. Similar
to the recurrent pancreatic injury model, increased infiltration of inflammatory cells and
extensive fibrosis are present, consistent with a chronic pancreatitis phenotype.
Furthermore, instances of ADM and more progressive PanIN lesions were present in the
tissue. The presence of PanIN lesions indicates the potential for progression to PDAC,
although full-blown pancreatic cancer was not observed in this study.

However, a study by Guerra et al., 2007 demonstrated that inducing KRAS activation in
adult mice, when combined with chronic pancreatitis, produced invasive PDA within 5
months of oncogenic KRAS activation. The pancreatic injury observed in the female
MKA mice indicates the presence of chronic pancreatitis. Due the presence of active
KRAS in this mouse model, it is likely that extending the length of this experiment past
two months could reveal the presence of PDAC in MKA female mice.
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Studies of ATRX mutation in other cancer types (including pancreatic neuroendocrine
tumours) demonstrate a strong correlation between loss of ATRX or its binding partner
DAXX and upregulation of the alternative lengthening of telomeres (ALT) pathway
(Lovejoy et al., 2010; Heaphy et al., 2011a). However, a study examining PDAC tumours
(n=448) confirmed the absence of ALT in every case (Heaphy et al., 2011b). Further,
PDAC is typically characterized by telomere attrition, with telomere shortening evident
in all PanIN grades (van Heek et al., 2002). This strongly suggests that unlike other
cancer types, loss of ATRX does not drive damage through an ALT phenotype. However,
to rule out this possibility, assessment of telomere length in lesions of the female MKA
mice could be performed.

The exact mechanism through which ATRX loss can promote activity of oncogenic
KRAS is unclear. A well characterized function of ATRX is mediating deposition of
histone variant H3.3, in conjunction with binding partner DAXX (Drane et al., 2010;
Lewis et al., 2010). Loss of ATRX, and subsequent alteration of H3.3 deposition, could
influence chromatin structure and modify gene expression, leading to activation of
oncogenic KRAS and/or downstream pathways which further potentiate KRAS activity.
Pathways downstream of KRAS are diverse and regulate many different cellular
processes, including proliferation and cell survival, which could promote pancreatic
damage (Castellano and Downward, 2011; Crespo et al., 2000). Performing similar
experiments with an inducible DAXX deletion could reveal if ATRX activity in this
model is DAXX-dependent. Alternatively, ATRX could be functioning in a DAXXindependent manner to influence gene expression, working in complex with other
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proteins or complexes, including PRC2. Previous literature has confirmed interaction
between ATRX and EZH2, a member of PRC2, leading to altered gene expression
(Cardoso et al., 1998; Sarma et al., 2014). Whole genome analysis of mRNA expression,
using RNA-sequencing of pancreatic tissue in mice, at a time point prior to the
development of damage, could demonstrate changes in gene expression and help to
pinpoint specific genes of interest.

4.2.4 Gender Specificity of Pancreatic Damage in MKA mice

The incidence of human PDAC between genders is relatively equal, with approximately
the same number of cases occurring in males and females (Canadian Cancer Statistics,
2016). However, it is possible that ATRX loss defines a unique subtype of PDAC, in
which the female population is more susceptible. The gender-specific mechanism
producing extensive pancreatic damage specifically in female MKA mice remains
unclear. In this study, female mice heterozygous (AtrxflΔ18/ x) or homozygous (AtrxflΔ18/
flΔ18

) for the mutant Atrx allele showed different results when combined with KRAS

activation. In mice that are heterozygous for the mutant Atrx allele (AtrxflΔ18/ x), it is
expected that approximately half of acinar cells will lose ATRX expression completely
due to X-inactivation of the wild-type Atrx allele. However, these mice did not
demonstrate increased damage with KRAS mutation, and were subsequently grouped
together with mice containing two wild-type Atrx alleles (Atrxx/ x) during analysis. These
results suggest that complete loss of ATRX in acinar tissue is required to produce
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pancreatic damage, possibly due to skewed X-inactivation of the chromosome containing
the mutant Atrx allele. Interestingly, the male MKA mice appear to have the opposite
effect from their female counterparts, showing a protective effect and decreased damage
with ATRX loss/KRAS activation.

There are three potential mechanisms through which MKA mice may have genderspecific differences in damage. First, hormonal factors could be considered to play a role.
Sex hormone receptors, including estrogen receptors (ER) have been known to play a role
in the progression of other cancers such as breast and colon (Nussler et al., 2008; Perou et
al., 2000). Further, specific rare types of pancreatic neoplasms, including papillary and
mucinous cystic neoplasms, have a higher incidence in females and have been linked to
ER upregulation (Kosumi et al., 2015; Satake et al., 2006). Estrogen receptors
(specifically ERa) can be activated by MAPK signaling, and can mediate regulation of
cellular growth and survival (Kato et al., 1995; Thomas and Gustafsson, 2011). It is
possible that increased KRAS activity, due to ATRX loss, in female MKA mice could
induce ER upregulation and growth factor signaling in acinar tissue. The level of
expression of estrogen receptors, or other sex hormone receptors (progesterone) within
pancreatic tissue of MKA mice could be assessed using immunohistochemical staining to
test this theory.

Second, it is possible that aberrant gene expression from the silenced X-chromosome
may occur with loss of ATRX. ATRX co-operates with polycomb repressive complex 2
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(PRC2) to mediate gene silencing, including inactivation of the X chromosome (XCI)
(Cardoso et al., 1998; Sarma et al., 2014). Loss of XCI has been demonstrated in other
cancer types including ovarian and breast cancer (Chaligne et al., 2015), and genes
located on the X chromosome have been implicated in cancer, including cancer/testis
antigen and the Wtx gene (Kang et al., 2015; Rivera et al., 2007). It is possible that reactivation of the X-chromosome with loss of ATRX could greatly increase the expression
of X-linked genes, an event which would be specific to female cohort of MKA mice. To
confirm this theory, RNA-sequencing of acinar tissue would allow for complete
assessment of changes in X-linked gene expression.

Finally, gender-specific mechanisms could be explained by a difference in inflammatory
response between male and female mice. It is possible that female mice with ATRX loss
are more susceptible to factors promoting inflammation, such as pancreatic injury. In
support of this theory, female Mist1creERT/+ AtrxflΔ18 mice that underwent recurrent
pancreatic injury showed increased inflammation in comparison to their male
counterparts, resulting in higher levels of damage. Accordingly, increased inflammation
in female MKA mice could lead to increased damage, promoting widespread lesion
formation. High levels of KRAS activity can induce senescence as a tumour suppressive
mechanism, termed oncogene-induced senescence (OIS) (Collado et al., 2005; Serrano et
al., 1997). Interestingly, Guerra et al., 2011 demonstrated that the presence of pancreatic
inflammation could overcome this senescent mechanism, contributing to the progression
of PDAC. In this model, an increased inflammatory response in female MKA mice could
amplify oncogenic KRAS and activation of downstream pathways, including MAPK and
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PI3K-PDK1-Akt signaling, leading to increased cell survival and proliferation.
Accordingly, increased KRASG12D activity by inflammatory cytokines, including NF-kB
and IL-6, has been demonstrated previously (Daniluk et al., 2012; Baumgart et al., 2014;
Lesina et al., 2011). The presence of an inflammatory response in the female MKA mice,
which is not observed in male MKA mice, could overcome OIS specifically within the
female cohort of mice, leading to increased damage. Assessment of senescent markers
within these mice could confirm this theory.

In summary, based on the results shown in this study, it is clear that ATRX loss can
enhance pancreatic injury or susceptibility to KRAS-mediated pancreatic damage.
Oncogenic KRASG12D mutation places the KRAS protein in a primed state, leading to
high levels of KRAS activity upon stimulation. It is proposed that ATRX loss is able to
promote high levels of KRAS activity, which may be attenuated in male MKA mice
through oncogene-induced senescence (OIS) leading to decreased damage (Figure 4.1).
Potential gender specific factors within female MKA mice (including hormonal factors, X
chromosome re-activation, or increased inflammation) may provide an additional driving
factor for KRAS activity and pancreatic damage, leading to a female-specific phenotype.
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Loss of ATRX

OIS
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Active KRAS

Senescent Acinar Cell

KRAS G12D
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Acinar Cell

Susceptible
Acinar Cell
Female

ADM

Loss of ATRX
Active KRAS
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Figure 4.1. Proposed model for the loss of ATRX contributing to KRASG12Dmediated PanIN formation. In this model, KRASG12D makes acinar cells susceptible to
further stimulation (including injury or further mutation). Loss of ATRX is sufficient to
stimulate high levels of KRAS activity, triggering oncogene-induced senescence (OIS) in
male mice and protecting acinar tissue from oncogenic transformation. In female mice,
additional gender-specific factors (possibly inflammatory or hormonal differences) allow
acinar cells to overcome OIS, leading to acinar-to-ductal metaplasia (ADM) and PanIN
formation.
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4.3 Limitations & Future Directions

This study defines a novel role for ATRX within the pancreas. However, there are
limitations to the experimental design which must be considered. The Mist1 gene, used to
drive cre-mediated recombination in this model, is specific to serous exocrine cells, and
thus provided an acinar-specific deletion of Atrx/activation of KRAS within the pancreas.
However, since MIST1 is expressed in other tissue types (including stomach and salivary
gland), Atrx deletion and expression of oncogenic KRAS also occurred in these tissues.
Therefore, there were non-pancreatic effects including the formation of tumours in the
stomach and mouth of these mice. This effectively limited the timeframe of this study,
and prevented the observation of pancreatic phenotype at potential later time points,
where PDAC is most likely to develop. Use of a different acinar-specific cre-driver (e.g.
Ptf1a) in future experiments would allow for longer-term studies. Furthermore, the dose
of pancreatitis used in the recurrent pancreatitis experiments was suboptimal (75 µg/ml),
compared to other studies which used similar cerulein administration protocols (Halbrook
et al., 2017) and showed more extensive damage in their mice. Use of a higher cerulein
dose in this experiment may have revealed greater differences between control mice and
mice lacking ATRX.

Moving forward, studies to further investigate the cooperation between ATRX loss and
KRAS activation will help to elucidate the exact mechanism through which this
phenotype occurs. Both cell-autonomous (dependent on ATRX loss within the cell) and
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non-cell autonomous (e.g. inflammation) mechanisms should be considered. Using cell
culture techniques, acinar cells from male and female mice lacking ATRX could be
isolated and plated in collagen matrix. The propensity of these cells to undergo
conversion to a duct-like state in culture can be assessed, to determine if there is an
inherent susceptibility to ADM in cells lacking ATRX (cell-autonomous event). Analysis
of gene expression using RNA-sequencing could identify the influence of ATRX loss on
gene expression, and potential pathways through which it may amplify KRAS activity.
To investigate possible non-cell autonomous factors, including inflammation, antiinflammatory treatments could be administered in these models of pancreatic injury and
KRAS-induced pancreatic damage. This would indicate the potential importance of
inflammation in mediating the phenotypes observed in this study.
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Appendices

Supplemental Table S1. Histology grading criteria

Acinar-to-ductal metaplasia (ADM)
(based on worst pancreatic lobule)
0
1
2
3
4

None present
>10% of lobule
10-30% of lobule
30-50% of lobule
>50% of lobule

Fibrosis
(based on Trichrome Stain)
0
1
2
3
4

None present
<5% of tissue area
5-10% of tissue area
10-20% of tissue area
>20% of tissue area

Inflammation
0
1
2
3
4

None present
Focal – small, contained areas
Mild – small, slightly diffuse areas
Moderate – diffuse areas
Severe – diffuse areas, significant presence throughout the tissue
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Supplemental Figure S1. Representative images of histological grading scale.
Representative histological images for each possible score (0-4) on the histological
grading scale utilized for recurrent pancreatitis and oncogenic KRAS models (see Table
3.1, 3.2). Three factors were assessed; inflammation, fibrosis (based on Trichrome stain),
and acinar-to-ductal metaplasia (ADM).
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TUNEL

Mist1 creERT/+Atrx flΔ18

!H2AX

Supplemental Figure S2. Increased gH2AX and TUNEL staining, 60 days following
loss of ATRX. Representative immunofluorescence indicates an increased number of
acinar cells positive for gH2AX and TUNEL staining (white arrows) in
Mist1creERT/+AtrxflΔ18, compared to control mice.
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Atrx flΔ18

LSL-KRAS G12D

MKA

Female

Male

Mist1 creERT/+

Supplemental Figure S3. Minor morphological differences visible in pancreatic
tissue, 60 days following Atrx deletion and/or oncogenic KRAS activation. (A)
Representative images of pancreas in situ in control, Mist1creERT/+AtrxflΔ18,
Mist1creERT/+LSL-KRASG12D and MKA mice (outlined by the dotted line). Edema is visible
in female MKA mice, as well as an enlarged spleen (indicated by white arrow).
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Supplemental Figure S4. Increased fibrosis in MKA mice compared to
Mist1creERT/+LSL-KRASG12D mice. (A) Masson’s Trichrome stain in control and
Mist1creERT/+AtrxflΔ18 saline or cerulein-treated mice, three days following cessation of
CIP treatment. (B) Trichrome stain in control, Mist1creERT/+AtrxflΔ18, Mist1creERT/+LSLKRASG12D mice, 60 days following tamoxifen gavage (blue indicates fibrosis, indicated
by black arrow).
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Supplemental Figure S5. PanIN lesions progress to PanIN2 in MKA female mice.
Representative H&E images of each grade of pancreatic lesion, ranging from ADM –
PanIN 2, evident in the acinar tissue of MKA female mice (black arrows).
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